

An audit of the practice of red packed cell transfusion in neonatal surgery in an academic hospital


Kushal Govender

A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg in partial fulfilment of the requirements for the degree of Master of Medicine in the branch of Anaesthesiology.

Johannesburg, 2022

Declaration

I, Kushal Govender declare that this research report is my own unaided work. It is being submitted for the Degree of Master of Medicine in the branch of Anaesthesiology at the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at any other University.



08 August 2022

Dedication

I dedicate this body of work to my family, who have always made unconditional sacrifices to support me in my endeavours. Thank you dearly.

Abstract

Background

Neonates undergoing surgery are at greater risk of requiring red packed cells transfusion. Paediatric transfusion practices vary widely between countries and institutions, especially in the management of neonates.

Aims

The aim of this study was to describe the practice of intraoperative red packed cells transfusion primarily, and blood products and fluid transfusion secondarily in neonates presenting for surgery.

Methods

A retrospective contextual and descriptive study was conducted at Chris Hani Baragwanath Academic Hospital. A total of 1077 anaesthetic records of neonates who underwent surgery from 1 January 2015 to 31 December 2019 were reviewed. Descriptive and inferential statistics were used to analyse the data.

Results

Three hundred and twenty seven (30%) neonates received intraoperative red packed cells transfusion. The median (IQR) volume of red packed cells, fresh frozen plasma, platelets and clear fluid administered was 15 (10 - 21.8) ml/kg, 12.3 (10 - 23.5) ml/kg, 13.6 (10 - 20.5) ml/kg and 19 (9.1 - 28.8) ml/kg respectively. Very low weight, low preoperative haemoglobin, long total anaesthetic time, emergency surgery and major surgery were independently associated with blood product transfusion. Post-conceptual age, low and very low weight, blood product transfusion and major surgery were independently associated with the composite adverse outcomes.

Conclusions

Intraoperative blood product transfusion occurred up to three times more frequently in our study than in comparative studies. Weight-based dosing of red packed cells, blood products and clear fluids were in keeping with current

recommendations. Further prospective cohort studies are recommended to inform an institution specific patient blood management programme.

Clinical Implications

Neonatal patient blood management programmes are informed by limited scientific data. Current evidence based guidelines do not address the perioperative period. An audit of transfusion practice is the first step in developing evidence based institutional perioperative neonatal transfusion guidelines.

Acknowledgements

I would like to thank the following people:

My supervisors, Prof Palesa Motshabi Chakane and Dr Ellen Kemp, for their limitless patience, unconditional support and guidance.

The statistician, Mr Michael Muteba, for his assistance with the statistical analysis.

Table of contents

Declaration	ii
Dedication.....	iii
Abstract	iv
Background.....	iv
Aims.....	iv
Methods.....	iv
Results.....	iv
Conclusions	iv
Clinical Implications.....	v
Acknowledgements.....	vi
Table of contents	vii
List of figures	ix
List of tables	x
List of appendices.....	xi
List of abbreviations	xii
Statement	xiii
Draft article	14
Abstract.....	15
Introduction	17
Methods	19

Results	20
Discussion.....	23
Limitations.....	26
Conclusions	26
Acknowledgement.....	27
Conflict of interest.....	27
References.....	28
Appendices.....	39

List of figures

Figure 1. Flow diagram of records included in the study.....	37
--	----

List of tables

Table 1. Baseline characteristics.	32
Table 2. Fluid and blood product transfusion profiles.....	33
Table 3. Morbidity outcomes.....	34
Table 4. Factors associated with blood product transfusion.....	35
Table 5. Factors associated with the composite of adverse outcomes	36

List of appendices

Appendix 1: Journal guideline to authors	39
Appendix 2: Literature review	58
Appendix 3: Study proposal	73
Appendix 4: Clearance from Human Research Ethics Committee	100
Appendix 5: Approval from Graduate Studies Committee.....	101
Appendix 6: Permission from Medical Advisory Committee	102
Appendix 7: Permission from Department of Anaesthesiology.....	103
Appendix 8: Permission from Department of Paediatric Surgery	104
Appendix 9: Turnitin report	105

List of abbreviations

ABG	Arterial blood gas
CHBAH	Chris Hani Baragwanath Academic Hospital
FFP	Fresh frozen plasma
Hb	Haemoglobin
ICU	Intensive care unit
PBM	Patient blood management
RPC	Red packed cell
SANBS	South African National Blood Service

Statement

The Research Report consists of a draft article and appendices. A literature review and the study proposal is included as appendices for background reference and is not for examination.

The formatting of this Research Report complies with the University of the Witwatersrand's Style Guide for Theses, Dissertations and Research Reports. The formatting of the draft article may differ from the Research Report in order to comply with the author guidelines of Pediatric Anesthesia, the journal to which it is intended to be submitted.

Draft article

An audit of the practice of red packed cell transfusion in neonatal surgery in an academic hospital

Running title: Transfusion practices and outcomes during neonatal surgery: a 5 year retrospective review

Kushal Govender, MBChB, DA (SA)¹

Ellen Kemp, FCA (SA)¹

Palesa Motshabi Chakane, BSc, MBChB, DA (SA), FCA (SA), PhD¹

*¹Department of Anesthesiology, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Department of Anesthesiology, Chris Hani Baragwanath Academic Hospital*

Corresponding Author: K Govender, Department of Anesthesiology, Chris Hani Baragwanath Academic Hospital, 26 Chris Hani Rd, Diepkloof, Soweto, Johannesburg, South Africa. Email: lahsuk@gmail.com; Contact Number: +27 11 933 9335; Orchid ID: <https://orcid.org/0000-0002-4636-3312>

Data availability statement: The data that supports the finding of this study are available on request from the corresponding author. The data are not publically available due to privacy or ethical restrictions.

Abstract

Background

Neonates undergoing surgery are at greater risk of requiring red packed cells transfusion. Pediatric transfusion practices vary widely between countries and institutions, especially in the management of neonates.

Aims

The aim of this study was to describe the practice of intraoperative red packed cells transfusion primarily, and blood products and fluid transfusion secondarily in neonates presenting for surgery.

Methods

A retrospective contextual and descriptive study was conducted at Chris Hani Baragwanath Academic Hospital. A total of 1077 anesthetic records of neonates who underwent surgery from 1 January 2015 to 31 December 2019 were reviewed. Descriptive and inferential statistics were used to analyze the data.

Results

Three hundred and twenty seven (30%) neonates received intraoperative red packed cells transfusion. The median (IQR) volume of red packed cells, fresh frozen plasma, platelets and clear fluid administered was 15 (10 - 21.8) ml/kg, 12.3 (10 - 23.5) ml/kg, 13.6 (10 - 20.5) ml/kg and 19 (9.1 - 28.8) ml/kg respectively. Very low weight, low preoperative hemoglobin, long total anesthetic time, emergency surgery and major surgery were independently associated with blood product transfusion. Post-conceptual age, low and very low weight, blood product transfusion and major surgery were independently associated with the composite adverse outcomes.

Conclusions

Intraoperative blood product transfusion occurred up to three times more frequently in our study than in comparative studies. Weight-based dosing of red packed cells, blood products and clear fluids were in keeping with current recommendations. Further prospective cohort studies are recommended to inform an institution specific patient blood management program.

Key words: blood transfusion; infant; newborn; surgery

Clinical Implications

Neonatal patient blood management programs are informed by limited scientific data. Current evidence based guidelines do not address the perioperative period. An audit of transfusion practice is the first step in developing evidence based institutional perioperative neonatal transfusion guidelines.

Introduction

The Pediatric Perioperative Cardiac Arrest (POCA) registry identified hypovolaemia resulting from blood loss as the most common cause of anesthesia related cardiac arrests.¹ Red packed cell (RPC) transfusion is a life-saving intervention for neonates and children undergoing surgery. While perioperative transfusion is uncommon in adults and older children, neonates tend to require RPC transfusion more frequently.² In the face of "anemia of infancy" simultaneous non-physiologic processes, such as bleeding, hemolysis, and impaired red cell production, may contribute to a clinically significant anemia, requiring intervention.³

Neonates undergoing surgery are at risk of requiring RPC transfusion owing to their small circulatory volumes, relatively high metabolic needs and inability to compensate for tissue oxygen demands in the face of anemia.⁴ The relationship between preoperative anemia and perioperative mortality in patients undergoing non-cardiac surgery has been described in adult⁵, pediatric⁶ and neonatal patient subpopulations.⁷

Following RPC's, platelet concentrate, the second most commonly administered blood component in neonates⁸, may be indicated in thrombocytopenia affecting up to 70% of extremely low birth weight neonates.⁹ Most platelet transfusions are administered to neonates with severe thrombocytopenia in the face of active hemorrhage.¹⁰ Neonates at risk of surgical hemorrhage amounting to more than 40% of the circulating blood volume may require both platelet and plasma transfusions.⁴

Evidence based Perioperative Blood Management (PBM) programs aim to optimize patient care by avoiding unnecessary transfusions and limiting adverse effects.¹¹ Currently, there is a paucity of literature specific to PBM in children with limited evidence based guidelines.¹² Various national and institutional pediatric transfusion guidelines vary in their recommendations regarding safe restrictive transfusion thresholds, particularly in the neonatal subgroup.¹³ While neonates undergo surgery and receive RPC transfusion at Chris Hani Baragwanath Academic Hospital (CHBAH), no departmental or institutional guidelines exist to guide intraoperative RPC transfusion practice.

We therefore embarked on a 5-year retrospective review of blood product transfusion practice and outcomes in neonatal patients presenting for surgery at CHBAH. The aim of this study was to describe the practice of intraoperative RPC transfusion primarily, and blood products and fluid transfusion secondarily in neonates presenting for surgery; to describe the association between patient factors, blood product transfusion and the composite of adverse outcomes and mortality. The composite of adverse outcomes was defined as the presence of any of the following outcomes: postoperative ICU admission, postoperative intubation/ventilation, and postoperative inotrope/vasopressor administration.

Methods

A retrospective, contextual and descriptive study was conducted in the theatre complex of CHBAH in Johannesburg, South Africa, for neonates who underwent surgery from 1 January 2015 to 31 December 2019. A consecutive, convenience sampling method was used. Each available record was assigned a study number and the reviewed variables were captured using Microsoft® Office Excel® 2007 software (Copyright 2006 Microsoft Corporation, One Microsoft Way, Redmond, Washington 98052 - 7329). The variables included are in Supplementary Table 1. Missing, illegible and incomplete records were excluded. All data was collected by one author (KG).

The hospital is the largest in Southern Africa with 2888 beds and is affiliated to the Faculty of Health Sciences of the University of the Witwatersrand. The hospital has 25 operating rooms of which one is used for neonatal surgery and

on average 120 neonatal surgeries are performed annually. Approval to conduct this study was obtained from the Human Research Ethics Committee (Medical) (M210419) and the Graduate Studies Committee of the University of the Witwatersrand as well as the Medical Advisory Committee of CHBAH.

Stata/SE 16 statistical software (Copyright 1985-2019 Stata Corp LLC, Stata Corp, 4905 Lakeway Drive College Station, Texas 77845) was used to analyze the data. Demographic data were reported as frequencies and percentages for categorical data, means and standard deviations for normally distributed data and medians and interquartile ranges for non-parametric data. Patient characteristics, blood product and fluid profiles, and postoperative blood gas parameters of patients who were transfused were compared to those who were not using independent t-tests when data was normally distributed, and Mann-Whitney tests when data was not normally distributed. A regression analysis was used to analyze associations between blood product transfusion, demographic factors and the composite of adverse outcomes and mortality. A p-value of <0.05 was considered statistically significant.

Results

A total of 1078 neonates had surgery in the institution during the study period (Figure 1). The mean (SD) gestational age at birth was 34.9 (4.6) weeks and 648 (60%) were male (Table 1). The median (IQR) chronological age was 21.4 (12 - 28) days, whilst the mean (SD) post-conceptual age was 34.4 (11.6) weeks. The mean (SD) weight was 2479.3 (844.3) grams. Five hundred and

fifty-one (51%) patients had emergency surgery and 697 (65%) had major surgery, predominantly intra-abdominal. Of the total, 374 (35%) had blood product transfusion, with 327 (30%) receiving RPC transfusion (Figure 1).

Neonates who were transfused had a significantly lower median (IQR) gestational age at birth, median (IQR) post-conceptual age, and median (IQR) weight, than those who were not transfused ($p < 0.001$). The median (IQR) chronological age of both transfused and non-transfused neonates were comparable at 12 (6 - 25.5) days and 12 (4 - 29) days respectively ($p = 0.307$).

The median (IQR) preoperative Hb in neonates who received intraoperative transfusion was significantly lower than those who did not [11.6 (9.8 - 13.6) g/dl vs. 14.2 (11.5 - 16.7) g/dl, ($p < 0.001$)]. A significantly larger proportion of neonates who received intraoperative transfusion underwent emergency surgery (65%), major surgery (92%) and had a longer median (IQR) total anesthetic time, 155 (115 - 205) minutes, ($p < 0.001$).

Amongst the patients who were transfused, the median (IQR) volume of RPC, fresh frozen plasma (FFP) and platelets transfused were 15 (10 - 23.5) ml/kg, 12.3 (10 - 23.5) ml/kg and 13.6 (10 - 20.5) ml/kg respectively (Table 2). The total median (IQR) volume of fluid (clear and blood products) per kg, administered to neonates who received intraoperative transfusion was approximately twice as much as that to neonates who were not transfused, 37.8 (25 - 57.5) ml/kg vs. 18.5 (10.2 - 30.3) ml/kg respectively ($p < 0.01$). The total

median (IQR) volume of clear fluid administered per hour was however comparable between groups, [19 (9.1 - 28.8) ml/kg and 18.5 (10.2 - 30.3) ml/kg respectively, (p=0.352)].

The postoperative median (IQR) Hb 11.8 (10.5 - 13.7) g/dl in neonates who were transfused was significantly lower compared to 13.2 (11 - 15.3) g/dl in those who were not transfused (p=0.001) (Table 2). The postoperative median (IQR) pH, pCO₂, pO₂ and BE were 7.32 (7.234 - 7.384), 43 (34.3 - 51.05) mmHg, 49.1 (39.1 - 79.9) mmHg and -4.1 (-7.6 - -0.9) respectively in those transfused. The median (IQR) postoperative lactate were higher amongst transfused neonates [2.5 (1.7 - 4.45) vs. (1.7 - 3.6) respectively, (p=0.02)].

The composite of adverse outcome occurred in 712/1078 (66%) neonates in total. Seven hundred and eight (65%) neonates were admitted to the ICU postoperatively. A total of 618 (57%) were intubated and ventilated while 117 (11%) required vasopressor/inotropic support (Table 3). The rate of ICU admission, postoperative intubation/ventilation and vasopressor administration were significantly higher in those who were transfused, (p<0.001).

Very low weight (aOR 4.02, 95% CI 1.77 - 9.12, p=0.001), preoperative Hb (aOR 0.68, 95% CI 0.63 - 0.74, p<0.001), total anesthetic time (aOR 1.01, 95% CI 1.01 - 1.01, p<0.001), emergency surgery (aOR 1.68, 95% CI 1.12 - 2.50, p=0.012) and major surgery (aOR 11.32, 95% CI 6.22 - 20.63, p<0.001) were independently associated with blood product transfusion (Table 4). Blood

product transfusion (aOR 4.27, 95% CI 2.55 - 7.16, $p < 0.001$), post-conceptual age in weeks (aOR 0.889, 95% CI 0.919 - 0.965, $p = 0.005$), low weight (aOR 3.60, 95% CI 2.27 - 5.72, $p < 0.001$), very low weight (aOR 6.41, 95% CI 2.23 - 18.40, $p = 0.001$), and major surgery (aOR 5.61, 95% CI 3.58 - 8.78, $p < 0.001$) were independently associated with the composite adverse outcome (Table 5).

Discussion

The major findings of this study show that patients who received red packed cells and blood product transfusion were predominantly premature with lower weight at time of surgery. Their surgeries were mostly major emergency surgery characterized by intra-abdominal surgery. They experienced prolonged surgical times and received a large total volume of fluid and blood product transfusion combined. They had presented with lower preoperative Hb and continued to have lower Hb postoperatively. Very low weight, preoperative low Hb and prolonged major surgery predisposed patients to blood product transfusion. Blood product transfusion in turn, together with post-conceptual age, low weight, very low weight and major surgery, were independently associated with the composite of adverse outcome.

The basis of well-informed PBM programs is robust clinical evidence. There is, however, a paucity of strong scientific data to support such programs and guidelines in the pediatric population.^{11, 13} Current international guidelines are heterogeneous as they are informed by limited scientific data and are hence based more on expert opinion. Therefore pediatric transfusion practices vary

widely between countries and institutions, especially in the management of neonates.¹⁴

Overall, our study found an increased frequency of intraoperative RPC transfusion (30%) in neonates who underwent surgery during the study period compared to reports of between 9.9% and 23.8% in previous studies.^{2, 15-17} Quinn et al¹⁶ and Keung et al² had found a relationship between low weight and laparotomy in neonates with increased risk of receiving perioperative RPC transfusion. Galvez et al¹⁷ found that lengthy procedures put patients at risk of perioperative blood product transfusion. The factors associated with transfusion in our study were comparable to those reported by Quinn et al¹⁶ and Keung et al.² A frequency of perioperative transfusion of between 27% and 30% has been reported amongst premature neonates with post-conceptual age less than 45 weeks.¹⁷ The proportion of neonates in our study with post-conceptual age less than 45 weeks may account for the increased frequency of transfusion observed.

Our institution does not have a prescribed transfusion trigger, however, the mean Hb preoperatively and postoperatively was maintained at approximately 11 g/dl. Several international societies recommend transfusion triggers of between 8.5 - 11 g/dl in neonates requiring mechanical ventilation.^{13, 18, 19}

The current South African National Blood Service (SANBS) Clinical Guidelines for the Use of Blood Products in South Africa recommends transfusion in an

acutely bleeding neonate when more than 10% of the blood volume is lost.²⁰ A transfusion trigger of 12 g/dl is recommended for neonates on mechanical ventilation while a more restrictive threshold of 8 - 11 g/dl is recommended for non-ventilated neonates still requiring supplementary oxygen support.²⁰ The guidelines do not address the perioperative conditions.

FFP and platelet transfusion seemed to follow the transfusion of RPC in our study at median (IQR) volumes of 12 (10 - 20) ml/kg and 13.6 (10 - 20.5) ml/kg respectively. They are indicated in dilutional coagulopathy following massive blood transfusion⁵ with a recommended dose of FFP of 10 - 20 ml/kg¹⁸⁻²⁰ and 10 - 20 ml/kg platelets transfusions^{4, 18-20} at a suggested threshold platelet count of $50 \times 10^9/L$ or lower.¹⁹ The intraoperative administration of blood products serve to replace ongoing losses with the aim of maintaining normovolaemia in the bleeding neonate. Amongst the neonates who were not transfused in our study, the intraoperative losses were replaced with clear fluid the volume of which was comparable to the clear fluid administered to transfused neonates.

Studies have demonstrated an association between RPC transfusion in preterm infants and significant morbidity including the development of necrotizing enterocolitis^{21, 22}, intraventricular haemorrhage²³, retinopathy of prematurity²⁴, circulatory and iron overload and bronchopulmonary dysplasia²². While a restrictive transfusion strategy has been shown to be safe in hemodynamically stable pediatric patients in the ICU setting²⁵, evidence of safety in the neonatal subpopulation in the face of ongoing surgical hemorrhage is still lacking.

Limitations

Despite limitations of this study, the findings approximated the recommendations of existing national and international guidelines for blood management practice in neonates. The study was limited by its retrospective nature. The cross-sectional design of this retrospective study is limited in its ability to investigate the cause and effect relationship between co-variates in this study, including preoperative Hb, RPC transfusion, and the composite of adverse outcome. Further prospective study may be required to differentiate between association and causality in this regard. The results of this study are contextual and can therefore not be generalized.

Conclusions

Intraoperative RPC and blood product transfusion occurred up to three times more frequently in our study than in comparative studies which may be subsequent to the lack of a strict institutional PBM program. However, despite the absence of an institutional PBM program to guide neonatal intraoperative RPC transfusion practice at CHBAH, this study found that RPC transfusion practice during neonatal surgery at CHBAH is closely adherent to both local and international recommendations. Weight-based dosing of RPCs, blood products and clear fluids were in keeping with current recommendations. Further prospective cohort studies are recommended in order to determine the cause and effect relationship between patient co-variates, blood product transfusion and morbidity outcomes in a stepwise approach to defining appropriate and

safe intraoperative transfusion triggers which in turn will aid in the development of an institution specific PBM program at CHBAH.

Acknowledgement

This research was done in partial fulfilment of a Master of Medicine degree.

Conflict of interest

The authors declare that we have no financial or personal relationships which may have inappropriately influenced us in writing this paper.

References

1. Bhananker SM, Ramamoorthy C, Geiduschek JM, Posner KL, Domino KB, Haberkern CM, et al. Anesthesia-related cardiac arrest in children: update from the Pediatric Perioperative Cardiac Arrest Registry. *Anesth Analg*. 2007;105(2):344-50. <https://doi.org/10.1213/01.ane.0000268712.00756.dd>.
2. Keung CY, Smith KR, Savoia HF, Davidson AJ. An audit of transfusion of red blood cell units in pediatric anesthesia. *Paediatr Anaesth*. 2009;19(4):320-8. <https://doi.org/10.1111/j.1460-9592.2009.02939.x>.
3. Widness JA. Pathophysiology of anemia during the neonatal period, including anemia of prematurity. *Neoreviews*. 2008;9(11):e520-e. <https://doi.org/10.1542/neo.9-11-e520>.
4. Bharadwaj A, Khandelwal M, Kumar Bhargava S. Perioperative neonatal and paediatric blood transfusion. *Indian J Anaesth*. 2014;58:652-7. <https://doi.org/10.4103/0019-5049.144679>.
5. Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. *Lancet*. 2011;378(9800):1396-407. [https://doi.org/10.1016/s0140-6736\(11\)61381-0](https://doi.org/10.1016/s0140-6736(11)61381-0).
6. Faraoni D, DiNardo JA, Goobie SM. Relationship between preoperative anemia and in-hospital mortality in children undergoing noncardiac surgery. *Anesth Analg*. 2016;123(6):1582-7. <https://doi.org/10.1213/ane.0000000000001499>.
7. Goobie SM, Faraoni D, Zurakowski D, DiNardo JA. Association of preoperative anemia with postoperative mortality in neonates. *JAMA Pediatr*.

- 2016;170(9):855-62. <https://doi.org/10.1001/jamapediatrics.2016.1032>.
8. Stanworth SJ. Thrombocytopenia, bleeding, and use of platelet transfusions in sick neonates. Hematology Am Soc Hematol Educ Program. 2012;2012:512-6. <https://doi.org/10.1182/asheducation-2012.1.512>.
9. Christensen RD, Henry E, Wiedmeier SE, Stoddard RA, Sola-Visner MC, Lambert DK, et al. Thrombocytopenia among extremely low birth weight neonates: data from a multihospital healthcare system. J Perinatol. 2006;26(6):348-53. <https://doi.org/10.1038/sj.jp.7211509>.
10. Dogra K, Kaur G, Basu S, Chawla D. Fresh frozen plasma and platelet transfusion practices in neonatal intensive care unit of a tertiary care hospital. Indian J Hematol Blood Transfus. 2020;36(1):141-8. <https://doi.org/10.1007/s12288-019-01164-z>.
11. Goel R, Cushing MM, Tobian AA. Pediatric patient blood management programs: not just transfusing little adults. Transfus Med Rev. 2016;30(4):235-41. <https://doi.org/10.1016/j.tmr.2016.07.004>.
12. Roseff SD, Luban NL, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. Transfusion. 2002;42(11):1398-413. <https://doi.org/10.1046/j.1537-2995.2002.00208.x>.
13. Lopriore E. Updates in red blood cell and platelet transfusions in preterm neonates. Am J Perinatol. 2019;36(S 02):S37-s40. <https://doi.org/10.1055/s-0039-1691775>.
14. Bednarek FJ, Weisberger S, Richardson DK, Frantz ID, Shah B, Rubin LP. Variations in blood transfusions among newborn intensive care units. SNAP II Study Group. J Pediatr. 1998;133(5):601-7. <https://doi.org/10.1016/s0022->

[3476\(98\)70097-6](#).

15. Dukleska K, Vinocur CD, Brenn BR, Lim DJ, Keith SW, Dirnberger DR, et al. Preoperative blood transfusions and morbidity in neonates undergoing surgery. *Pediatrics*. 2020;146(5). <https://doi.org/10.1542/peds.2019-3718>.
16. Quinn N, Figgins H, Doherty C, Wilkinson D. NeoNatal periOperative Transfusion Evaluation Study: NeoNOTES: Association of Paediatric Anaesthetists of Great Britain and Ireland. 2018. Available from: <https://www.apagbi.org.uk/sites/default/files/inline-files/P10.pdf>.
17. Gálvez JA, Ahumada L, Simpao AF, Lin EE, Bonafide CP, Choudhry D, et al. Visual analytical tool for evaluation of 10-year perioperative transfusion practice at a children's hospital. *J Am Med Inform Assoc*. 2014;21(3):529-34. <https://doi.org/10.1136/amiajnl-2013-002241>.
18. Lau W. *Clinical Guide to Transfusion: Canadian Blood Services*. 2017. Available from: <https://professionaleducation.blood.ca/en/transfusion/guide-clinique/neonatal-and-pediatric-transfusion>.
19. New HV, Berryman J, Bolton-Maggs PH, Cantwell C, Chalmers EA, Davies T, et al. Guidelines on transfusion for fetuses, neonates and older children. *Br J Haematol*. 2016;175(5):784-828. <https://doi.org/10.1111/bjh.14233>.
20. South African National Blood Services. Clinical guidelines for the use of blood products in South Africa. 2014. Available from: https://sanbs.org.za/wp-content/uploads/2016/09/Clinical_Guidelines_5th-Edition_2014.pdf.
21. Iskander IF, Salama KM, Gamaleldin RM, Seghatchian J. Neonatal RBC transfusions: Do benefits outweigh risks? *Transfus Apher Sci*. 2018;57(3):431-

6. <https://doi.org/10.1016/j.transci.2018.05.007>.
22. Mohamed A, Shah PS. Transfusion associated necrotizing enterocolitis: a meta-analysis of observational data. *Pediatrics*. 2012;129(3):529-40. <https://doi.org/10.1542/peds.2011-2872>.
23. Christensen RD, Baer VL, Lambert DK, Ilstrup SJ, Eggert LD, Henry E. Association, among very-low-birthweight neonates, between red blood cell transfusions in the week after birth and severe intraventricular hemorrhage. *Transfusion*. 2014;54(1):104-8. <https://doi.org/10.1111/trf.12234>.
24. Wang Y-C, Chan O-W, Chiang M-C, Yang P-H, Chu S-M, Hsu J-F, et al. Red blood cell transfusion and clinical outcomes in extremely low birth weight preterm infants. *Pediatr Neonatol*. 2017;58(3):216-22. <https://doi.org/10.1016/j.pedneo.2016.03.009>.
25. Franz AR, Engel C, Bassler D, Rüdiger M, Thome UH, Maier RF, et al. Effects of liberal vs restrictive transfusion thresholds on survival and neurocognitive outcomes in extremely low-birth-weight infants: the ETTNO randomized clinical trial. *Jama*. 2020;324(6):560-70. <https://doi.org/10.1001/jama.2020.10690>.

Table 1. Baseline characteristics.

Parameter	Transfused		Not Transfused		P Value
	n	median (IQR) / (%)	n	median (IQR) / (%)	
Gestation at birth (weeks)	349	33 (30 – 37)	619	36 (32 – 40)	<0.001
Chronological age (days)	372	12 (6 – 25.5)	702	12 (4 – 29)	0.307
Post-conceptual age (weeks)	374	35.5 (32.4 – 39.6)	704	39.5 (35 – 41.3)	<0.001
Weight (g)	371	1960 (1410 – 2500)	691	2700 (2100 – 3250)	<0.001
Preoperative hemoglobin (g/dl)	351	11.6 (9.8 – 13.6)	550	14.2 (11.5 – 16.7)	<0.001
Anesthetic time (minutes)	374	155 (115 – 205)	704	115 (85 – 155)	<0.001
Gender-Male	203	55	431	62	0.027
Emergency surgery	245	65.5	306	43.5	<0.001
Major surgery	344	92	353	50.2	<0.001

Table 2. Fluid and blood product transfusion profiles.

Parameter	Transfused		Not Transfused		P Value
	n	median (IQR)	n	median (IQR)	
RPC vol (ml)	326	30 (20 – 42)	0	-	-
RPC vol (ml/kg)	325	15 (10 – 21.8)	0	-	-
RPC vol rate (ml/kg/hr)	325	5.6 (3.6 – 9.3)	0	-	-
FFP vol (ml)	85	20 (15 – 30)	0	-	-
FFP vol (ml/kg)	85	12.3 (10 – 20.5)	0	-	-
FFP vol rate (ml/kg/hr)	85	5.6 (4 – 8.1)	0	-	-
Platelets vol (ml)	133	25 (15 – 32)	0	-	-
Platelets vol (ml/kg)	133	13.6 (10 – 20.5)	0	-	-
Platelets vol rate (ml/kg/hr)	133	6.9 (4.4 – 11.1)	0	-	-
Clear fluid vol (ml)	316	35 (18.5 – 60)	635	50 (29 – 80)	<0.001
Clear fluid vol (ml/kg)	314	19 (9.1 – 28.8)	626	18.5 (10.2 – 30.3)	0.352
Clear fluid vol rate (ml/kg/hr)	314	6.6 (3.9 – 10.4)	626	9 (5.6 – 14.4)	<0.001
Total fluid and blood product (ml)	374	71 (48 – 110)	635	50 (29 – 80)	<0.001
Total fluid and blood product (ml/kg)	372	37.8 (25 – 57.5)	626	18.5 (10.2 – 30.3)	<0.001
Total fluid and blood product rate (ml/kg/hr)	372	15 (9.5 – 22.5)	626	9 (5.6 – 14.4)	<0.001
Postoperative hemoglobin (g/dl)	206	11.8 (10.5 – 13.7)	161	13.2 (11 – 15.3)	0.001
Postoperative lactate	156	2.5 (1.7 – 4.45)	113	2.5 (1.7 – 3.6)	0.020
Postoperative pCO ₂ (mmHg)	216	43 (34.3 – 51.05)	169	40.4 (34.8 – 47.4)	0.118
Postoperative pH	217	7.32 (7.234 – 7.384)	173	7.335 (7.263 -7.416)	0.111
Postoperative pO ₂ (mmHg)	212	49.1 (39.1 – 79.9)	171	50.5 (38.3 – 113)	0.323
Postoperative base excess	207	-4.1 (-7.6 – -0.9)	170	-3.8 (-6.6 – -1.3)	0.548

* RPC - red packed cells, FFP - fresh frozen plasma, vol - volume, pCO₂ - partial pressure of carbon dioxide, pO₂ - partial pressure of oxygen.

Table 3. Morbidity outcomes.

Outcome Parameter		Transfused	Not Transfused	All	P Value
		n (%)	n (%)	n (%)	
Postoperative Intensive Care Unit	Yes	345 (94)	363 (52)	708 (66)	<0.001
	No	23 (6)	335 (48)	358 (34)	
Postoperative Intubation/Ventilation	Yes	331 (90)	287 (41)	618 (58)	<0.001
	No	37 (10)	411 (59)	448 (42)	
Vasopressor/Inotrope	Yes	90 (24)	27 (4)	117 (11)	<0.001
	No	279 (76)	673 (96)	952 (89)	

Table 4. Factors associated with blood product transfusion.

Parameter		uOR (95% CI)	P Value	aOR (95% CI)	P Value
Gestation at birth weeks		0.89 (0.86 - 0.91)	<0.001	0.93 (0.87 - 1.00)	0.051
Chronological age days		1.00 (0.99 - 1.00)	0.106	1.00 (0.98 - 1.01)	0.504
Post-conceptual age weeks		0.99 (0.98 - 1.01)	0.329	-	-
Gender:-Males		0.75 (0.58 - 0.97)	0.027	0.93 (0.63 - 1.36)	0.692
Weight (g)		1.00 (1.00 - 1.00)	<0.001	-	-
Birth weight categories	Macrosomia	0.54 (0.23 - 1.31)	0.175	0.87 (0.21 - 3.52)	0.844
	Normal	1 (Base)	-	1 (base)	-
	Low	3.16 (2.33 - 4.27)	<0.001	1.58 (0.97 - 2.57)	0.064
	Very low	11.45 (7.20 - 18.23)	<0.001	4.02 (1.77 - 9.12)	0.001
	Extremely low	15.27 (4.17 - 55.86)	<0.001	3.93 (0.67 - 23.11)	0.130
Preoperative hemoglobin (g/dl)		0.79 (0.75 - 0.83)	<0.001	0.68 (0.63 - 0.74)	<0.001
Anesthetic time		1.01 (1.01 - 1.01)	<0.001	1.01 (1.01 - 1.01)	<0.001
Emergency surgery		2.5 (1.9 - 3.2)	<0.001	1.68 (1.12 - 2.50)	0.012
Major surgery		11.4 (7.61 - 17.00)	<0.001	11.32 (6.22 - 20.63)	<0.001

Table 5. Factors associated with the composite of adverse outcomes.

Parameter	uOR (95% CI)	P Value	aOR (95% CI)	P Value
Gestation at birth	0.931 (0.903 - 0.960)	<0.001	1.045 (0.983 - 1.110)	0.158
Post-conceptual age	0.986 (0.974 - 0.997)	0.017	0.889 (0.919 - 0.965)	0.005
Weight	0.9985 (0.9983 - 0.9987)	<0.001	-	-
Macrosomia	0.23 (0.11 - 0.48)	<0.001	0.42 (0.16 - 1.13)	0.087
Normal weight	1 (Base)	-	1 (Base)	-
Low weight	5.82 (4.21 - 8.03)	<0.001	3.60 (2.27 - 5.72)	<0.001
Very low weight	15.24 (7.28 - 31.94)	<0.01	6.41 (2.23 - 18.40)	0.001
Extremely low weight	-	-	-	-
Gender (Male)	0.65 (0.50 - 0.85)	0.002	1.02 (0.70 - 1.48)	0.934
Blood product transfusion	11.94 (7.85 - 18.14)	<0.001	4.27 (2.55 - 7.16)	<0.001
Anesthetic time	1.01 (1.01 - 1.01)	<0.001	1.00 (1.00 - 1.00)	0.615
Emergency surgery	3.38 (2.59 - 4.42)	<0.001	1.21 (0.82 - 1.81)	0.339
Major surgery	14.44 (10.63 - 19.62)	<0.001	5.61 (3.58 - 8.78)	<0.001




Figure 1. Flow diagram of records included in the study.

Supplementary Table 1. Patient variables.

Variable
Gestational age at birth
Chronological age
Post-conceptual age
Gender
Weight
Co-morbidities
Indication for surgery
Surgical procedure performed
Total anesthetic time
Preoperative hemoglobin
Volume of RPC transfused intraoperatively
Volume of clear fluids administered intraoperatively
Postoperative hemoglobin
Postoperative ICU admission
Postoperative intubation and ventilation
Postoperative inotrope/vasopressor administration

* RPC - red packed cells, ICU - Intensive Care Unit

Appendices

Appendix 1: Journal guideline to authors

Journal: Pediatric Anesthesia

Contents

1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Preparing Your Submission
5. Editorial Policies and Ethical Considerations
6. Publication Process After Acceptance
7. Post Publication
8. Editorial Office Contact Details

1. SUBMISSION

Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at <https://mc.manuscriptcentral.com/pan>.

Click [here](#) for more details on how to use ScholarOne.

This Journal does not charge submission fees.

Open Access

Pediatric Anesthesia is part of Wiley's open access program offering an open access option within hybrid (subscription based) journals. With open access, on

acceptance of your paper, you can choose to pay an Article Publication Charge (APC) to make the article immediately, freely available online for all to read, download, and share. You can learn more on our Open Access page.

Funder Open Access: Please click [here](#) for more information on Wiley's compliance with specific Funder Open Access Policies.

Data Sharing and Data Accessibility

The journal expects authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.

Review [Wiley's Data Sharing policy](#) where you will be able to see and select the data availability statement that is right for your submission.

Data protection

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at <https://authorservices.wiley.com/statements/data-protection-policy.html>.

Preprint policy

This journal will consider for review papers previously available as preprints on non-commercial servers such as ArXiv, bioRxiv, psyArXiv, SocArXiv, engrXiv, etc. Authors may also post the submitted version of a manuscript to non-commercial servers at any time. Authors are requested to update any pre-publication versions with a link to the final published paper.

For help with submissions, please contact: paneditorialoffice@gmail.com.

Funding

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: <http://www.crossref.org/fundingdata/registry.html>

Authorship

The journal follows the [ICMJE definition of authorship](#), which indicates that authorship be based on the following 4 criteria:

- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- Drafting the work or revising it critically for important intellectual content; AND
- Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work he or she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their co-authors.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged. These authorship criteria are intended to reserve the status of authorship for those who deserve credit and can take responsibility for the work. The criteria are not intended for use as a means to disqualify colleagues from authorship who otherwise meet authorship criteria by denying them the opportunity to meet criterion #s 2 or 3. Therefore, all individuals who meet the first criterion should have the opportunity to participate in the review,

drafting, and final approval of the manuscript.

ORCID

As part of our commitment to supporting authors at every step of the publishing process, *Pediatric Anesthesia* requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. [Find more information.](#)

Reproduction of Copyright Material

If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is your responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit [Wiley's Copyright Terms & Conditions FAQ.](#)

The corresponding author is responsible for obtaining written permission to reproduce the material "in print and other media" from the publisher of the original source, and for supplying Wiley with that permission upon submission.

2. AIMS AND SCOPE

Pediatric Anesthesia's mission is to advance the science and clinical practice of paediatric anaesthesia, pain management and peri-operative medicine through dissemination of research, education and quality improvement.

Devoted to the dissemination of research of interest and importance to practising anaesthetists everywhere, the scientific and clinical content of *Pediatric Anesthesia* covers a wide selection of medical disciplines in all areas relevant to paediatric anaesthesia, pain management and peri-operative medicine. The Section Editors are supported by an international Editorial Board, Associate Editors and a bank of expert reviewers, who review and assess the scientific quality and relevance of all submissions to ensure that the journal is publishing the best evidence to guide clinical practice and future research. The journal publishes a range of papers including research reports, educational reviews, systematic

reviews, focused reviews, special interest articles, case reports, short reports, correspondence, and editorials.

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

Article Types

Research Report

Description

Research reports describe systematic original scientific investigations. The text body must include an introduction, materials and methods, results and discussion. All research reports must adhere to the journal [minimal reporting standards](#). Reports that do not adhere to these standards cannot be considered for publication.

Word Limit

3500 words

Maximum figures and tables – 6

Maximum references – 25

Abstract/Summary

Structured abstract up to 300 words Background; Aims; Methods; Results; Conclusions.

Other Requirements

In Clinical Implications, add 1-2 sentences answering:

- a. What is already known about the topic
- b. What new information this study adds (indicate the salient research results)

Guidelines for specific papers

Randomised clinical trials (RCTs) must conform to the CONSORT statement (<http://www.consort-statement.org>) on the reporting of RCTs. A [flow diagram of subjects](#), the trial protocol, and the registration details of the trial must be included in the paper, along with and a numbered checklist provided as supplementary material. Clinical trials MUST be registered in a recognised clinical trial registry prior to the start of the trial.

Diagnostic studies must conform to the STARD statement <http://www.stard-statement.org>. A flow diagram of subjects, the trial protocol, and the registration details of the trial must be included in the paper along with and a checklist provided as supplementary material.

Qualitative research – authors should refer to the EQUATOR NETWORK resource guidance on good research reporting (<http://www.equator-network.org>), which has the full suite of reporting guidelines (both quantitative and qualitative).

Observational studies (Epidemiology): Please follow the **STROBE** guidelines [http:// www.strobe-statement.org](http://www.strobe-statement.org) and submit the study protocol as supplementary material.

Systematic reviews/ meta-analysis of randomised trials and other evaluation studies must conform to PRISMA guidelines <http://www.prisma-statement.org> (these have superseded the QUOROM guidelines) and submit the study protocol as supplementary material.

Guidelines for Medicine Ingredient Names

Authors should ensure that drug names included in their submission align with any names used internationally. These guidelines can be found at: <https://www.tga.gov.au/updating-medicine-ingredient-names-list-affected-ingredients#active>.

4. PREPARING YOUR SUBMISSION

Cover Letters

A covering letter must be included, signed by the corresponding author and stating on behalf of all the authors that the work has not been published and is not being considered for publication elsewhere.

Parts of the Manuscript

The manuscript should be submitted in separate files: main text file; figures.

The manuscript should be double-spaced with 30mm margins. Manuscripts must be numbered consecutively in the following sequence: Title Page; Abstract and key words, if required; Main Body of Text; References; Tables and Figure caption List.

- i. Title page
- ii. Abstract and keywords
- iii. Main body of text; including Acknowledgements, Conflict of Interest Statement
- iv. References
- v. Tables (each table complete with title and footnotes)
- vi. Figure captions
- vii. Appendices including Footnotes (if relevant).

Figures and supporting information should be supplied as separate files.

Title page

- i. A short informative title containing the major key words. The title cannot be a statement of fact. The title should not contain abbreviations (see Wiley's [best practice SEO tips](#));

- ii. A short running title of less than 40 characters;
- iii. The full names of the authors; List each contributor's name and institutional affiliation. Please refer to the journal's Authorship policy in the Editorial Policies and Ethical Considerations section for details on author listing eligibility.
- iv. Corresponding Author: Provide the name, postal and e-mail address, fax and telephone number of the contributor responsible for the manuscript and proofs. This is the person to whom all correspondence will be sent. The corresponding author is responsible for keeping the editorial office updated with any change in details until the paper is published.
- v. The author's institutional affiliations where the work was conducted, with a footnote for the author's present address if different from where the work was conducted.

Abstract and Keywords

The abstract must not include abbreviations and must have complete sentences. Please provide 3-6 keywords. Keywords should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at <https://www.nlm.nih.gov/mesh/>.

Main body of text

Follow the structure of paper type as outlined in the Table above.

If a method or tool is introduced in the study, including software, questionnaires, and scales, the author should state the license this is available under and any requirement for permission for use. If an existing method or tool is used in the research, the authors are responsible for checking the license and obtaining the permission. If permission was required, a statement confirming permission should be included in the Methods and Materials section.

Acknowledgments

Contributions from anyone who does not meet the criteria for authorship should be

listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.

Conflict of Interest Statement

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to, patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

References

All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order using Arabic superscript numerals. Sample references follow:

Journal article:

1. King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. *J Comp Neurol.* 1998;390:537-551.

Book:

2. Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.

Please note that journal title abbreviations should conform to the practices of

Chemical Abstracts. For more information about AMA reference style, [AMA Manual of Style](#).

Tables

Tables should be self-contained and complement, not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order). Statistical measures such as SD or SEM should be identified in the headings.

Figure Legends

Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Figures

Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted.

[Click here](#) for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

Color figures. Figures submitted in color may be reproduced in color online free of charge. Please note, however, that it is preferable that line figures (e.g. graphs and charts) are supplied in black and white so that they are legible if printed by a reader in black and white.

Footnotes

Footnotes should be placed as a list at the end of the paper only, not at the foot of each page. They should be numbered in the list and referred to in the text with consecutive, superscript Arabic numerals. Keep footnotes brief; they should contain only short comments tangential to the main argument of the paper and should not include references.

Additional Files

Supporting Information

Supporting information is information that is not essential to the article but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc.

[Click here](#) for Wiley's FAQs on supporting information.

Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

General Style Points

The following points provide general advice on formatting and style.

- The journal uses US spellings
- Abbreviations: In general, abbreviations should be avoided. Terms should not be abbreviated unless they are used repeatedly, and the abbreviation is already well known to all readers. Initially, use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only. Abbreviations for medications or treatments are not acceptable.
- Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau International des Poids et Mesures (BIPM) website for more information about SI units.

- Numbers: numbers under 10 are spelled out, except for: measurements with a unit (8mmol/l); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils).
- Trade Names: Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name and the name and location of the manufacturer in parentheses.

Wiley Author Resources

Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission available [here](#). In particular, we encourage authors to consult Wiley's best practice tips on [Writing for Search Engine Optimization](#).

Article Preparation Support

[Wiley Editing Services](#) offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence. Also, check out our resources for [Preparing Your Article](#) for general guidance about writing and preparing your manuscript.

Wiley has an [Online Video Broadcast Release form](#) available to use.

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Peer Review and Acceptance

The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are single-blind peer reviewed. Papers will only be sent to review if the Editor-in-Chief determine that the paper meets the appropriate quality and relevance requirements.

Wiley's policy on confidentiality of the review process is available [here](#).

Minimal Reporting standards

All research reports submitted to the journal must comply with the [minimal reporting standards](#) for data this journal. Papers not meeting this requirement may be rejected without review.

Guidelines on Publishing and Research Ethics in Journal Articles Please review Wiley's policies surrounding human studies, animal studies, clinical trial registration, biosecurity, and research reporting guidelines [here](#).

Proteins sequence data should be submitted to either of the following repositories:

- Protein Information Resource (PIR): pir.georgetown.edu
- SWISS-PROT: expasy.ch/sprot/sprot-top

Human study guidelines

Manuscripts concerned with human studies must contain statements indicating that informed, written consent has been obtained from the patient/parent or guardian and submitted as a form.

A statement describing explicitly the ethical background to this study and any institutional or national ethical committee approval has been included in the manuscript. Or a statement with details of the exception from ethical review that has been granted by the relevant body. The study must comply with the ethical principles and guidelines of the relevant countries where the study was performed and the nations of the study's sponsor.

If individuals might be identified from a publication (e.g. from images, audio, video) authors must obtain explicit consent from the individuals/parents or guardian and submitted as a form. If in some circumstances it has been impossible or impractical with the best endeavours of those concerned to contact the patient/parent or guardian, the journal will consider publishing these images.

The journal refers to the [World Health Medical Association Declaration of Taipei on Ethical Considerations Regarding Health Databases and Biobanks](#).

Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used). Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent for to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained. Wiley has a [patient consent form](#) available for use.

Publication Ethics

This journal is a member of the [Committee on Publication Ethics \(COPE\)](#). Note this journal uses iThenticate's CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley's Top 10 Publishing Ethics Tips for Authors [here](#). Wiley's Publication Ethics Guidelines can be found [here](#).

Conflict of interest

Any conflict of interest needs to be declared.

A conflict of interest exists when professional judgment concerning a primary interest (such as patients' welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry).

The following accepted in the past five years from an organisation that may in any way gain or lose financially from the results of your study or the conclusions of your article would be considered a conflict of interest:

- Reimbursement for attending a symposium
- A fee for speaking
- A fee for organising education

- Funds for research
- Funds for a member of staff or your laboratory
- Fees for consultancy
- Have you in the past five years been employed by an organisation in excess of US\$10 000 that may in any way gain or lose financially from the results of your study or the conclusions of your article?
- Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the results of your study or the conclusions of your article?
- Do you have any other conflicting interests?

Authorship

The journal follows the [ICMJE authorship guidelines](#).

Prospective Trial Registration

In order to be published in *Pediatric Anesthesia*, all interventions must have been registered in an Internationally recognised platform including any one of the primary registries in the WHO registry network, or an [ICMJE approved registry](#) at the beginning of the research process (prior to patient recruitment). The following information must be provided: trial registration number, date registered, the date the first participant was recruited, and the date of ethics approval. If your paper reports a clinical trial, you must complete and upload [this form](#) when submitting your manuscript.

Prospective trial registration serves many purposes:

- i. It avoids duplication of effort because others know the work is going on
- ii. It aims to enhance the quality of trial reporting by making the protocol a matter of public record and therefore making selective reporting of

outcomes and post hoc protocol changes less likely and ensuring they are explicitly acknowledged as such

- iii. Most importantly, it ensures the safety and explicit informed consent of participants in advance of any treatment or intervention commencing.

For these reasons, *Pediatric Anesthesia* does not consider unregistered, or retrospectively registered trials.

The journal follows the [WHO definition of a clinical trial](#).

6. PUBLICATION PROCESS AFTER ACCEPTANCE

Author Services

When your accepted article is received by Wiley's production team, you (corresponding author) will receive an email asking you to login or register with [Author Services](#).

Author Licensing

If your paper is accepted, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services, where via the Wiley Author Licensing Service (WALS) they will be required to complete a copyright license agreement on behalf of all authors of the paper.

Authors may choose to publish under the terms of the journal's standard copyright agreement, or [OnlineOpen](#) under the terms of a Creative Commons License.

General information regarding licensing and copyright is available [here](#). To review the Creative Commons License options offered under OnlineOpen, please [click here](#). (Note that certain funders mandate that a particular type of CC license has to be used; to check this please [click here](#).)

Self-Archiving definitions and policies. Note that the journal's standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. Please click [here](#) for more detailed information about self-archiving definitions and policies.

Accepted Articles

The journal offers Wiley's Accepted Articles service for all manuscripts. This service ensures that accepted 'in press' manuscripts are published online very soon after acceptance, prior to copy-editing or typesetting. Accepted Articles are published online a few days after final acceptance, appear in PDF format only, are given a Digital Object Identifier (DOI), which allows them to be cited and tracked, and are indexed by PubMed. After publication of the final version article (the article of record), the DOI remains valid and can continue to be used to cite and access the article.

Accepted Articles will be indexed by PubMed; submitting authors should therefore carefully check the names and affiliations of all authors provided in the cover page of the manuscript so it is correct for indexing. Subsequently the final copyedited and proofed article will appear in an issue on Wiley Online Library; the link in PubMed will automatically be updated.

Proofs

Once the paper is typeset, the author will receive an email notification with full instructions on how to access HTML page proofs online. Please note that the author is responsible for all statements made in their work, including changes made during the editorial process – authors should check proofs carefully. Note that proofs should be returned within 48 hours from receipt of the email.

Early View

The journal offers rapid publication via Wiley's Early View service. [Early View](#) (Online Version of Record) papers are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before the paper appears online, as Editors also need to review proofs. Before we can publish a paper, we require a signed license (authors should login or register with Wiley Author Services. Once the article is published on Early View, no further changes to the article are possible. Please note Editorials are not published on Early View. The Early View article is fully citable and carries an online publication date and DOI for citations.

7. POST PUBLICATION

Access and sharing

When your paper is published online:

- The author receives an email alert (if requested).
- The link to the published article can be shared through social media.
- The author will have free access to the paper (after accepting the Terms & Conditions of use, they can view the article).
- For non-open access articles, the corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to the paper.

Article Promotion Support

[Wiley Editing Services](#) offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.

Measuring the Impact of your Work

Wiley also helps you measure the impact of your research through our specialist partnerships with [Kudos](#) and [Altmetric](#).

Archiving Services

Portico and CLOCKSS are digital archiving/preservation services we use to ensure that Wiley content will be accessible to customers in the event of a catastrophic event such as Wiley going out of business or the platform not being accessible for a significant period of time. Member libraries participating in these services will be able to access content after such an event. Wiley has licenses with both Portico and CLOCKSS, and all journal content gets delivered to both services as it is published on Wiley Online Library. Depending on their integration mechanisms, and volume loads, there is always a delay between content being

delivered and showing as “preserved” in these products.

8. EDITORIAL OFFICE CONTACT DETAILS

For queries about submissions, please contact: paneditorialoffice@gmail.com.

Appendix 2: Literature review

Literature review

1. Introduction

This literature review will begin with a brief discussion of neonatal physiology with respect to anaemia. The benefits and risks associated with red packed cell (RPC) transfusion in neonates, current transfusion practice recommendations, evidence based transfusion triggers and the role of patient blood management programmes will be then be reviewed.

2. Neonatal physiology

Neonatal surgery may result in major blood loss (1), requiring blood transfusion in order to correct the resulting acute anaemia (2). The Paediatric Perioperative Cardiac Arrest Registry identified hypovolaemia resulting from blood loss as the most common cause of anaesthesia-related cardiac arrests (3). RPC transfusion is a common life-saving intervention for neonates and children undergoing surgery. While perioperative transfusion is uncommon in adults and older children, neonates tend to require RPC transfusion more frequently (4).

Normal haemoglobin (Hb) levels have a wide range in neonates at birth. Normal levels range from 14 – 22 g/dl and progressively decrease to a nadir of 10 – 12 g/dl in term infants by 2 - 3 months (5). This decline is physiological and attributable to changes that occur during birth and transition to extrauterine life. The factors contributing to this change include: a shorter neonatal red blood cell lifespan; a progressive change in affinity of haemoglobin (Hb) for oxygen as foetal Hb transitions to adult Hb; an increase in neonatal red blood cell 2,3-diphosphoglycerate levels; neonatal cardiovascular compensatory mechanisms; and a decrease in plasma erythropoietin levels (6). The resulting "anaemia of infancy" is usually well tolerated and generally requires no intervention (7). Preterm and very low birth weight neonates are at increased risk of a more profound decline in Hb levels resulting in a nadir of 7 - 8 g/dl (6). Simultaneous non-physiologic processes, such as bleeding, haemolysis, and impaired red cell

production, may contribute to a clinically significant anaemia, requiring intervention (6, 8).

3. Benefits of RPC transfusion in neonates

RPC transfusion is indicated in cases of clinically significant anaemia, the most frequent of which is anaemia resulting from surgical or perinatal haemorrhagic shock and anaemia of prematurity (9). Venkatesh et al. (5) reports that "red cell transfusion remains the only treatment for the majority of cases of neonatal anaemia". When Hb levels drop below a critical threshold, a neonate will be unable to increase oxygen delivery to tissues despite compensatory increases in cardiac output (10). Following RPC transfusion, Hb levels increase and improve oxygen carrying capacity of blood. In so doing, oxygen delivery to tissues is improved. Numerous studies have shown that decreases in heart rate, cardiac output and fractional oxygen extraction occurs following transfusion of RPCs to infants with anaemia, hence reducing myocardial workload (11-13). Further benefits of RPC transfusion in neonates include a reduction in the incidence of apnoeic episodes (14) and a reduction in the need for intermittent positive pressure ventilation (15). Data from a study by Zagol et al. (16) showed that apnoeic episodes were less frequent in neonates with higher haematocrit levels (16). However, while RPC transfusion may be beneficial to replace blood loss during neonatal surgery, its utility has to be balanced against the potential risks.

4. Risks associated with RPC transfusion in neonates

RPC transfusion is associated with potential infectious and non-infectious risks, to which children are more vulnerable (17). Children, and in particular infants, have a higher incidence of adverse effects following transfusion than their adult counterparts as documented by the Serious Hazards of Transfusion (SHOT) Report (18). Out of 1867 cases reported in the SHOT report, 7.1% were in paediatric patients. Of these, 37.9% were in infants and 44% of this subgroup were neonates. The majority of paediatric reports were related to human error in either, the transfusion of incorrect blood products, avoidable transfusions, under transfusion, over transfusion, or lack of knowledge of specific requirements in blood products ordered (18, 19).

The three main causes of mortality following transfusion reported were transfusion related acute lung injury (TRALI), transfusion associated circulatory overload (TACO) and haemolytic transfusion reactions (20). Neonates are further at risk of necrotizing enterocolitis (NEC), intraventricular haemorrhage (IVH), retinopathy of prematurity (ROP), circulatory and iron overload, and bronchopulmonary dysplasia (BPD) following transfusion (21). Transfusion associated necrotizing enterocolitis (TANEC) is defined as an enterocolitis occurring within 48 hours of a transfusion (21). While retrospective studies (22, 23) debate whether NEC is in fact associated with recent blood transfusion, a study by Patel et al. (24) confirmed that NEC occurred twice as often in transfused neonates than in those who did not receive a transfusion.

Studies by Christensen et al. (25) and Bear et al. (26) confirmed that transfusions were associated with an increased risk of severe IVH particularly during the first week of life. A study by Yu-Cheng Wang indicated an association between transfusion and ROP (27), while another study by Dani et al. (28) implicated iron overload resulting from RPC transfusion with ROP most likely through oxidative injury from free radical formation (28). The oxidative stress resulting from iron overload may be implicated in the development of further disease such as BPD and the aforementioned NEC and ROP. With mounting evidence that transfusion during the neonatal period is not without associated risk, guidelines are necessary in order to direct appropriate transfusion practice.

5. Current transfusion practice recommendations

Guidelines by the South African National Blood Service (SANBS) (29), British Committee for Standards in Haematology (30), the Australian National Blood Authority (31) and the Canadian Blood Services (32) all recommend a small volume transfusion of 10 - 20 ml/kg of RPC for transfusion in a neonate in order to correct anaemia. However, the number of studies informing this consensus is extremely limited. A small study by Paul et al. (33) compared 10 versus 20 ml/kg RPC volume in very low birth weight infants and reported that 20 ml/kg volume resulted in a higher post transfusion Hb without any detrimental effects on pulmonary function.

A further study by Wong et al. (34) compared outcomes in infants receiving 15 versus 20 ml/kg RPC volume and found that fewer transfusions were necessary in the 20 ml/kg group without adverse effects. An observational study compared 15 versus 20 ml/kg RPC volume and found a reduction in the number of transfusions required when 20 ml/kg was used (35). Only one study investigated the optimal rate at which RPCs should be transfused and found that while slower rates of transfusion were associated with less haemodynamic disturbances, more rapid transfusion increased ejection fraction (36). The optimal transfusion volume in preterm neonates remains unknown. Whilst the guidelines may agree upon the recommended volume to be transfused, there is less consensus about the transfusion threshold at which a neonate should be transfused.

6. Evidence based transfusion triggers

Robust evidence supports a restrictive transfusion strategy in adult patients without adverse impact on clinical outcomes (37). This forms the basis of successful and well-informed patient blood management (PBM) programmes in this patient subgroup. There is, however, a paucity of strong scientific data to support such programmes and guidelines in the paediatric population (38-40). Only one large multicentre trial, the Transfusion Requirements in Paediatric Intensive Care Units (TRIPICU) trial (41), supports a restrictive transfusion strategy in children. The study compared transfusion at a liberal threshold of 9.5g/dl to a restrictive threshold of 7g/dl and found no benefits in using a liberal threshold (41). The study fell short in informing guidelines in neonatal patients undergoing surgery because the results could not be applied to patients with active bleeding or haemodynamic instability and the recommendation could not be extrapolated to premature infants.

Furthermore, studies comparing liberal versus restrictive thresholds in neonates need to account for differing thresholds according to gestation, postnatal age and comorbidity, as neonatal physiology is dynamic during this period. Three systematic reviews have evaluated the results of trials comparing restrictive versus liberal transfusion thresholds in preterm infants admitted to intensive care units. All three reviews found no significant difference in short term morbidity and mortality between neonates transfused at restrictive or liberal thresholds. However, the

studies included were underpowered to investigate long term outcomes of neonates transfused at restrictive thresholds, and again, were not in actively bleeding patients (42-44).

Conflicting data from studies have resulted in uncertainty surrounding neurological outcomes in neonates transfused at more restrictive thresholds (45-47). Some literature suggests that extremely low-birth-weight infants may be more susceptible to neurocognitive sequelae following transfusion at restrictive thresholds(45). However, a large multicenter trial, The Effects of Transfusion Thresholds on Neurocognitive Outcomes in Extremely Low-Birth-Weight Infants (ETTNO) trial (48), found no difference in neurological outcomes at a corrected gestational age of 24 months in extremely low-birth-weight neonates transfused at a restrictive threshold and those transfused at a liberal threshold (48). The results of the ongoing trial, the Transfusion of Prematures (TOP) trial (49), may soon add to the growing knowledge base and address this disparity.

7. The role of patient blood management programmes

Current international guidelines are heterogenous as they are informed by limited scientific data and are hence based more on expert opinion. Therefore paediatric transfusion practices vary widely between countries and institutions, especially in the management of neonates (50). The SANBS Clinical Guidelines for the Use of Blood Products in South Africa recommends transfusion in an acutely bleeding infant, less than four months old, when more than 10% of the blood volume is lost (29). Recommended transfusion triggers for anaemia or in infants receiving mechanical ventilation are Hb levels less than or equal to 12 g/dl (29). The transfusion trigger in infants not requiring mechanical ventilation is stated as a Hb level less than or equal to 8 - 11 g/dl (51).

An overview of other international transfusion thresholds is shown in Table 1 below. The University of Kwazulu-Natal School of Clinical Medicine has published guidelines for neonatal and paediatric transfusion that are in agreement with the SANBS guidelines (51) as shown in Table 2 below. However, the University of the Witwatersrand as well as Chris Hani Baragwanath Academic Hospital (CHBAH) currently have no institutional guidelines to inform practice in this regard. In order

to optimise the care of patients requiring transfusion, a PBM programme should be developed. This will provide an opportunity to optimise care by avoiding unnecessary transfusions and limiting the potential for adverse effects (39). In order to develop a robust PBM programme, current institutional transfusion practice needs to be audited.

Table 1: Overview of international guidelines and triggers for RPC transfusion in neonates - Adapted from Updates in Red Blood Cell and Platelet Transfusions in Preterm Neonates (38).

Postnatal age	British Committee for Standards in Haematology (2016)		Australian National Blood Authority (2016)		Canadian Blood Service (2017)		Dutch Guidelines Quality Council (2019)	
	Resp support	No resp support	Resp support	No Resp support	Resp support	No Resp support	Resp support	No resp support
Week 1	10-12 g/dl	10 g/dl	11-13 g/dl	10-12 g/dl	11.5 g/dl	10 g/dl	11.5 g/dl	10 g/dl
Week 2	9.5-10 g/dl	7.5 g/dl	10-12.5 g/dl	8.5-11 g/dl	10 g/dl	8.5 g/dl	10 g/dl	8.5 g/dl
Week 3	8.5-10 g/dl	7.5 g/dl	8.5-11 g/dl	7-10 g/dl	8.5 g/dl	7.5 g/dl	8.5 g/dl	7.5 g/dl

Table 2: Overview of local guidelines and triggers for RPC transfusion in infants < 4months of age - Adapted from SANBS Clinical Guidelines for the Use of Blood Products in South Africa (29) and University of Kwazulu-Natal School of Clinical Medicine Guidelines for Neonatal & Paediatric Transfusion (51).

South African National Blood Services (2014)		University of Kwazulu-Natal School of Clinical Medicine (2016)	
Clinical condition	Trigger	Clinical condition	Trigger
Anaemia in the first 24 hours	< 12 g/dl	Preterm/term born anaemic	12 g/dl
Mechanical ventilation	< 12 g/dl	Severe pulmonary disease	12-14 g/dl
Acute blood loss	> 10% blood volume lost	Acute blood loss > 10% estimated blood volume	12 g/dl
Oxygen dependant (not ventilated)	< 8-11 g/dl	Chronic oxygen dependency	11 g/dl
Late anaemia, stable patient (off oxygen)	> 7 g/dl	Late anaemia stable patient	7 g/dl

8. Summary

In this review, neonatal physiology with respect to anaemia, the benefits and risks of RPC transfusion in neonates, current transfusion practice recommendations, evidence based transfusion triggers and the role of patient blood management programmes was discussed.

9. References

1. Mannucci PM, Levi M. Prevention and treatment of major blood loss. *N Engl J Med*. 2007;356(22):2301-11. <https://doi.org/10.1056/NEJMra067742>.
2. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. *Anesthesiology*. 2006;105(1):198-208. <https://doi.org/10.1097/00000542-200607000-00030>.
3. Bhananker SM, Ramamoorthy C, Geiduschek JM, Posner KL, Domino KB, Haberkern CM, et al. Anesthesia-related cardiac arrest in children: update from the Pediatric Perioperative Cardiac Arrest Registry. *Anesth Analg*. 2007;105(2):344-50. <https://doi.org/10.1213/01.ane.0000268712.00756.dd>.
4. Keung CY, Smith KR, Savoia HF, Davidson AJ. An audit of transfusion of red blood cell units in pediatric anesthesia. *Paediatr Anaesth*. 2009;19(4):320-8. <https://doi.org/10.1111/j.1460-9592.2009.02939.x>.
5. Venkatesh V, Khan R, Curley A, New H, Stanworth S. How we decide when a neonate needs a transfusion. *Br J Haematol*. 2013;160(4):421-33. <https://doi.org/10.1111/bjh.12095>.
6. Widness JA. Pathophysiology of anemia during the neonatal period, including anemia of prematurity. *Neoreviews*. 2008;9(11):e520-e. <https://doi.org/10.1542/neo.9-11-e520>.
7. O'Brien RT, Pearson HA. Physiologic anemia of the newborn infant. *J Pediatr*. 1971;79(1):132-8. [https://doi.org/10.1016/S0022-3476\(71\)80076-8](https://doi.org/10.1016/S0022-3476(71)80076-8).
8. Strauss RG. Anaemia of prematurity: pathophysiology and treatment. *Blood Rev*. 2010;24(6):221-5. <https://doi.org/10.1016/j.blre.2010.08.001>.
9. Whyte RK, Jefferies AL, Canadian Paediatric Society Fetus and Newborn Committee. Red blood cell transfusion in newborn infants. *Paediatr Child health*.

2014;19(4):213-22. <https://doi.org/10.1093/pch/19.4.213>.

10. Bharadwaj A, Khandelwal M, Kumar Bhargava S. Perioperative neonatal and paediatric blood transfusion. *Indian J Anaesth.* 2014;58:652-7.

<https://doi.org/10.4103/0019-5049.144679>.

11. Bard H, Fouron J-C, Chessex P, Widness JA. Myocardial, erythropoietic, and metabolic adaptations to anemia of prematurity in infants with bronchopulmonary dysplasia. *J Pediatr.* 1998;132(4):630-4.

[https://doi.org/10.1016/S0022-3476\(98\)70351-8](https://doi.org/10.1016/S0022-3476(98)70351-8).

12. Lachance C, Chessex P, Fouron J-C, Widness JA, Bard H. Myocardial, erythropoietic, and metabolic adaptations to anemia of prematurity. *J Pediatr.* 1994;125(2):278-82.

[https://doi.org/https://doi.org/10.1016/S0022-3476\(94\)70211-X](https://doi.org/https://doi.org/10.1016/S0022-3476(94)70211-X).

13. Fredrickson LK, Bell EF, Cress GA, Johnson KJ, Zimmerman MB, Mahoney LT, et al. Acute physiological effects of packed red blood cell transfusion in preterm infants with different degrees of anaemia. *Arch Dis Child Fetal Neonatal Ed.* 2011;96(4):F249-F53. <https://doi.org/10.1136/adc.2010.191023>.

14. Stute H, Greiner B, Linderkamp O. Effect of blood transfusion on cardiorespiratory abnormalities in preterm infants. *Arch Dis Child Fetal Neonatal Ed.* 1995;72(3):F194-6. <https://doi.org/10.1136/fn.72.3.f194>.

15. Bell EF, Strauss RG, Widness JA, Mahoney LT, Mock DM, Seward VJ, et al. Randomized Trial of Liberal Versus Restrictive Guidelines for Red Blood Cell Transfusion in Preterm Infants. *Pediatrics.* 2005;115(6):1685.

<https://doi.org/10.1542/peds.2004-1884>.

16. Zagol K, Lake DE, Vergales B, Moorman ME, Paget-Brown A, Lee H, et al. Anemia, apnea of prematurity, and blood transfusions. *J Pediatr.* 2012;161(3):417-21.e1. <https://doi.org/10.1016/j.jpeds.2012.02.044>.

17. Stainsby D, Jones H, Wells AW, Gibson B, Cohen H, on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. Adverse outcomes of blood transfusion in children: analysis of UK reports to the serious hazards of

transfusion scheme 1996–2005. *Br J Haematol.* 2008;141(1):73-9.

<https://doi.org/10.1111/j.1365-2141.2008.07022.x>.

18. Poles D, et al, on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2019 Annual SHOT Report. 2020. Available from:

<https://www.shotuk.org/wp-content/uploads/myimages/SHOT-REPORT-2019-Final-Bookmarked-v2.pdf>.

19. Poles D, et al, on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2018 Annual SHOT Report. 2019. Available from:

https://www.shotuk.org/wp-content/uploads/myimages/SHOT-Report-2018_Web_Version-1.pdf.

20. Lavoie J. Blood transfusion risks and alternative strategies in pediatric patients. *Paediatr Anaesth.* 2011;21(1):14-24. <https://doi.org/10.1111/j.1460-9592.2010.03470.x>.

21. Iskander IF, Salama KM, Gamaleldin RM, Seghatchian J. Neonatal RBC transfusions: Do benefits outweigh risks? *Transfus Apher Sci.* 2018;57(3):431-6.

<https://doi.org/10.1016/j.transci.2018.05.007>.

22. Mohamed A, Shah PS. Transfusion associated necrotizing enterocolitis: a meta-analysis of observational data. *Pediatrics.* 2012;129(3):529-40.

<https://doi.org/10.1542/peds.2011-2872>.

23. Wallenstein MB, Arain YH, Birnie KL, Andrews J, Palma JP, Benitz WE, et al. Red blood cell transfusion is not associated with necrotizing enterocolitis: a review of consecutive transfusions in a tertiary neonatal intensive care unit. *J Pediatr.* 2014;165(4):678-82.

<https://doi.org/10.1016/j.jpeds.2014.06.012>.

24. Patel RM, Knezevic A, Shenvi N, Hinkes M, Keene S, Roback JD, et al. Association of red blood cell transfusion, anemia, and necrotizing enterocolitis in very low-birth-weight infants. *Jama.* 2016;315(9):889-97.

<https://doi.org/10.1001/jama.2016.1204>.

25. Christensen RD, Baer VL, Lambert DK, Ilstrup SJ, Eggert LD, Henry E. Association, among very-low-birthweight neonates, between red blood cell

- transfusions in the week after birth and severe intraventricular hemorrhage. *Transfusion*. 2014;54(1):104-8. <https://doi.org/10.1111/trf.12234>.
26. Baer VL, Lambert DK, Henry E, Snow GL, Butler A, Christensen RD. Among very-low-birth-weight neonates is red blood cell transfusion an independent risk factor for subsequently developing a severe intraventricular hemorrhage? *Transfusion*. 2011;51(6):1170-8. <https://doi.org/10.1111/j.1537-2995.2010.02980.x>.
27. Wang Y-C, Chan O-W, Chiang M-C, Yang P-H, Chu S-M, Hsu J-F, et al. Red blood cell transfusion and clinical outcomes in extremely low birth weight preterm infants. *Pediatr Neonatol*. 2017;58(3):216-22. <https://doi.org/10.1016/j.pedneo.2016.03.009>.
28. Dani C, Martelli E, Bertini G, Pezzati M, Rossetti M, Buonocore G, et al. Effect of blood transfusions on oxidative stress in preterm infants. *Arch Dis Child Fetal Neonatal Ed*. 2004;89(5):F408. <https://doi.org/10.1136/adc.2003.037085>.
29. South African National Blood Services. Clinical guidelines for the use of blood products in South Africa. 2014. Available from: https://sanbs.org.za/wp-content/uploads/2016/09/Clinical_Guidelines_5th-Edition_2014.pdf.
30. New HV, Berryman J, Bolton-Maggs PH, Cantwell C, Chalmers EA, Davies T, et al. Guidelines on transfusion for fetuses, neonates and older children. *Br J Haematol*. 2016;175(5):784-828. <https://doi.org/10.1111/bjh.14233>.
31. National Blood Authority (NBA). Patient Blood Management Guidelines: Module 6 - Neonatal and Paediatrics. Canberra, Australia; 2016. Available from: https://www.blood.gov.au/system/files/14523_NBA-Module-6-Neonat_Paediatrics_internals_5_updated_14_May_2020.pdf.
32. Lau W. Clinical Guide to Transfusion: Canadian Blood Services. 2017. Available from: <https://professionaleducation.blood.ca/en/transfusion/guide-clinique/neonatal-and-pediatric-transfusion>.
33. Paul DA, Leef KH, Locke RG, Stefano JL. Transfusion volume in infants with very low birth weight: a randomized trial of 10 versus 20 ml/kg. *J Pediatr*

Hematol Oncol. 2002;24(1):43-6.

34. Wong H, Connelly R, Day A, Flavin MP. A comparison of high and standard blood transfusion volumes in premature infants. *Acta Paediatrica*. 2005;94(5):624-5. <https://doi.org/10.1111/j.1651-2227.2005.tb01949.x>.

35. Khodabux CM, Hack KE, von Lindern JS, Brouwers H, Walther FJ, Brand A. A comparative cohort study on transfusion practice and outcome in two Dutch tertiary neonatal centres. *Transfus Med*. 2009;19(4):195-201. <https://doi.org/10.1111/j.1365-3148.2009.00934.x>.

36. Nose Y, Tamai H, Shimada S, Funato M. Haemodynamic effects of differing blood transfusion rates in infants less than 1500 g. *J Paediatr Child Health*. 1996;32(2):177-82. <https://doi.org/10.1111/j.1440-1754.1996.tb00918.x>.

37. Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev*. 2016;10:CD002042. <https://doi.org/10.1002/14651858.CD002042.pub4>.

38. Lopriore E. Updates in red blood cell and platelet transfusions in preterm neonates. *Am J Perinatol*. 2019;36(S 02):S37-s40. <https://doi.org/10.1055/s-0039-1691775>.

39. Goel R, Cushing MM, Tobian AA. Pediatric patient blood management programs: not just transfusing little adults. *Transfus Med Rev*. 2016;30(4):235-41. <https://doi.org/10.1016/j.tmr.2016.07.004>.

40. Goobie SM, Gallagher T, Gross I, Shander A. Society for the advancement of blood management administrative and clinical standards for patient blood management programs. 4th edition (pediatric version). *Paediatr Anaesth*. 2019;29(3):231-6. <https://doi.org/10.1111/pan.13574>.

41. Lacroix J, Hebert PC, Hutchison JS, Hume HA, Tucci M, Ducruet T, et al. Transfusion strategies for patients in pediatric intensive care units. *N Engl J Med*. 2007;356(16):1609-19. <https://doi.org/10.1056/NEJMoa066240>.

42. Venkatesh V, Khan R, Curley A, Hopewell S, Doree C, Stanworth S. The safety and efficacy of red cell transfusions in neonates: a systematic review of randomized controlled trials. *Br J Haematol*. 2012;158(3):370-85. <https://doi.org/10.1111/j.1365-2141.2012.09180.x>.
43. Whyte RK, Kirpalani H, Asztalos EV, Andersen C, Blajchman M, Heddle N, et al. Neurodevelopmental outcome of extremely low birth weight infants randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion. *Pediatrics*. 2009;123(1):207-13. <https://doi.org/10.1542/peds.2008-0338>.
44. Ibrahim M, Ho SK, Yeo CL. Restrictive versus liberal red blood cell transfusion thresholds in very low birth weight infants: a systematic review and meta-analysis. *J Paediatr Child Health*. 2014;50(2):122-30. <https://doi.org/10.1111/jpc.12409>.
45. Kirpalani H, Whyte RK, Andersen C, Asztalos EV, Heddle N, Blajchman MA, et al. The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. *J Pediatr*. 2006;149(3):301-7. <https://doi.org/10.1016/j.jpeds.2006.05.011>.
46. McCoy TE, Conrad AL, Richman LC, Lindgren SD, Nopoulos PC, Bell EF. Neurocognitive profiles of preterm infants randomly assigned to lower or higher hematocrit thresholds for transfusion. *Child Neuropsychol*. 2011;17(4):347-67. <https://doi.org/10.1080/09297049.2010.544647>.
47. Nopoulos PC, Conrad AL, Bell EF, Strauss RG, Widness JA, Magnotta VA, et al. Long-term outcome of brain structure in premature infants: effects of liberal vs restricted red blood cell transfusions. *Arch Pediatr Adolesc Med*. 2011;165(5):443-50. <https://doi.org/10.1001/archpediatrics.2010.269>.
48. Franz AR, Engel C, Bassler D, Rüdiger M, Thome UH, Maier RF, et al. Effects of Liberal vs Restrictive Transfusion Thresholds on Survival and Neurocognitive Outcomes in Extremely Low-Birth-Weight Infants: The ETTNO Randomized Clinical Trial. *Jama*. 2020;324(6):560-70. <https://doi.org/10.1001/jama.2020.10690>.

49. Kirpalani H, Bell E, D'Angio C, Hintz S, Kennedy K, Ohls R, et al. Transfusion of Prematures (TOP) Trial: Does a liberal red blood cell transfusion strategy improve neurologically-intact survival of extremely-low-birth-weight infants as compared to a restrictive strategy? 2012. https://doi.org/https://www.nichd.nih.gov/sites/default/files/about/Documents/TOP_Protocol.pdf.
50. Bednarek FJ, Weisberger S, Richardson DK, Frantz ID, Shah B, Rubin LP. Variations in blood transfusions among newborn intensive care units. SNAP II Study Group. J Pediatr. 1998;133(5):601-7. [https://doi.org/10.1016/s0022-3476\(98\)70097-6](https://doi.org/10.1016/s0022-3476(98)70097-6).
51. Mpofu A. Guidelines For Neonatal & Paediatric Transfusion. University of Kwazulu-Natal; 2016. Available from: http://anaesthetics.ukzn.ac.za/Libraries/ICU_1/FMM_4_26-02-2016_Guidelines_for_Neonatal_paediatric_transfusion_Mpofu.sflb.ashx.

Appendix 3: Study proposal

An audit of the practice of red packed cell transfusion in neonatal surgery in an academic hospital

Kushal Govender

0604091X

Supervisor: Dr Ellen Kemp

Department of Anaesthesiology

Co-supervisor: Dr Palesa Motshabi

Department of Anaesthesiology

1. Introduction

1.1. Neonatal physiology

Neonatal surgery may result in major blood loss (1), requiring blood transfusion in order to correct the resulting acute anaemia (2). The Paediatric Perioperative Cardiac Arrest Registry identified hypovolaemia resulting from blood loss as the most common cause of anaesthesia-related cardiac arrests (3). Red packed cell (RPC) transfusion is a common life-saving intervention for neonates and children undergoing surgery. While perioperative transfusion is uncommon in adults and older children, neonates tend to require RPC transfusion more frequently (4).

Normal haemoglobin (Hb) levels have a wide range in neonates at birth. Normal levels range from 14 – 22 g/dl and progressively decrease to a nadir of 10 – 12 g/dl in term infants by 2 - 3 months (5). This decline is physiological and attributable to changes that occur during birth and transition to extrauterine life.

The factors contributing to this change include: a shorter neonatal red blood cell lifespan; a progressive change in affinity of haemoglobin (Hb) for oxygen as foetal Hb transitions to adult Hb; an increase in neonatal red blood cell 2,3-diphosphoglycerate levels; neonatal cardiovascular compensatory mechanisms; and a decrease in plasma erythropoietin levels (6). The resulting "anaemia of infancy" is usually well tolerated and generally requires no intervention (7).

Preterm and very low birth weight neonates are at increased risk of a more profound decline in Hb levels resulting in a nadir of 7 - 8 g/dl (6). Simultaneous non-physiologic processes, such as bleeding, haemolysis, and impaired red cell production, may contribute to a clinically significant anaemia, requiring intervention (6, 8).

1.2. Benefits of RPC transfusion in neonates

RPC transfusion is indicated in cases of clinically significant anaemia, the most frequent of which is anaemia resulting from surgical or perinatal haemorrhagic shock and anaemia of prematurity (9). Venkatesh et al. (5) reports that "red cell transfusion remains the only treatment for the majority of cases of neonatal anaemia". When Hb levels drop below a critical threshold, a neonate will be unable to increase oxygen delivery to tissues despite compensatory increases in cardiac

output (10). Following RPC transfusion, Hb levels increase and improve oxygen carrying capacity of blood. In so doing, oxygen delivery to tissues is improved. Numerous studies have shown that decreases in heart rate, cardiac output and fractional oxygen extraction occurs following transfusion of RPCs to infants with anaemia, hence reducing myocardial workload (11-13). Further benefits of RPC transfusion in neonates include a reduction in the incidence of apnoeic episodes (14) and a reduction in the need for intermittent positive pressure ventilation (15). Data from a study by Zagol et al. (16) showed that apnoeic episodes were less frequent in neonates with higher haematocrit levels (16). However, while RPC transfusion may be beneficial to replace blood loss during neonatal surgery, its utility has to be balanced against the potential risks.

1.3. Risks associated with RPC transfusion in neonates

RPC transfusion is associated with potential infectious and non-infectious risks, to which children are more vulnerable (17). Children, and in particular infants, have a higher incidence of adverse effects following transfusion than their adult counterparts as documented by the Serious Hazards of Transfusion (SHOT) Report (18). Out of 1867 cases reported in the SHOT report, 7.1% were in paediatric patients. Of these, 37.9% were in infants and 44% of this subgroup were neonates. The majority of paediatric reports were related to human error in either, the transfusion of incorrect blood products, avoidable transfusions, under transfusion, over transfusion, or lack of knowledge of specific requirements in blood products ordered (18, 19).

The three main causes of mortality following transfusion reported were transfusion related acute lung injury (TRALI), transfusion associated circulatory overload (TACO) and haemolytic transfusion reactions (20). Neonates are further at risk of necrotizing enterocolitis (NEC), intraventricular haemorrhage (IVH), retinopathy of prematurity (ROP), circulatory and iron overload, and bronchopulmonary dysplasia (BPD) following transfusion (21). Transfusion associated necrotizing enterocolitis (TANEC) is defined as an enterocolitis occurring within 48 hours of a transfusion (21). While retrospective studies (22, 23) debate whether NEC is in fact associated with recent blood transfusion, a study by Patel et al. (24) confirmed that NEC

occurred twice as often in transfused neonates than in those who did not receive a transfusion.

Studies by Christensen et al. (25) and Bear et al. (26) confirmed that transfusions were associated with an increased risk of severe IVH particularly during the first week of life. A study by Yu-Cheng Wang indicated an association between transfusion and ROP (27), while another study by Dani et al. (28) implicated iron overload resulting from RPC transfusion with ROP most likely through oxidative injury from free radical formation (28). The oxidative stress resulting from iron overload may be implicated in the development of further disease such as BPD and the aforementioned NEC and ROP. With mounting evidence that transfusion during the neonatal period is not without associated risk, guidelines are necessary in order to direct appropriate transfusion practice.

1.4. Current transfusion practice recommendations

Guidelines by the South African National Blood Service (SANBS) (29), British Committee for Standards in Haematology (30), the Australian National Blood Authority (31) and the Canadian Blood Services (32) all recommend a small volume transfusion of 10 - 20 ml/kg of RPC for transfusion in a neonate in order to correct anaemia. However, the number of studies informing this consensus is extremely limited. A small study by Paul et al. (33) compared 10 versus 20 ml/kg RPC volume in very low birth weight infants and reported that 20 ml/kg volume resulted in a higher post transfusion Hb without any detrimental effects on pulmonary function.

A further study by Wong et al. (34) compared outcomes in infants receiving 15 versus 20 ml/kg RPC volume and found that fewer transfusions were necessary in the 20 ml/kg group without adverse effects. An observational study compared 15 versus 20 ml/kg RPC volume and found a reduction in the number of transfusions required when 20 ml/kg was used (35). Only one study investigated the optimal rate at which RPCs should be transfused and found that while slower rates of transfusion were associated with less haemodynamic disturbances, more rapid transfusion increased ejection fraction (36). The optimal transfusion volume in preterm neonates remains unknown. Whilst the guidelines may agree upon the

recommended volume to be transfused, there is less consensus about the transfusion threshold at which a neonate should be transfused.

1.5 Evidence based transfusion triggers

Robust evidence supports a restrictive transfusion strategy in adult patients without adverse impact on clinical outcomes (37). This forms the basis of successful and well-informed patient blood management (PBM) programmes in this patient subgroup. There is, however, a paucity of strong scientific data to support such programmes and guidelines in the paediatric population (38-40). Only one large multicentre trial, the Transfusion Requirements in Paediatric Intensive Care Units (TRIPICU) trial (41), supports a restrictive transfusion strategy in children. The study compared transfusion at a liberal threshold of 9.5g/dl to a restrictive threshold of 7g/dl and found no benefits in using a liberal threshold (41). The study fell short in informing guidelines in neonatal patients undergoing surgery because the results could not be applied to patients with active bleeding or haemodynamic instability and the recommendation could not be extrapolated to premature infants.

Furthermore, studies comparing liberal versus restrictive thresholds in neonates need to account for differing thresholds according to gestation, postnatal age and comorbidity, as neonatal physiology is dynamic during this period. Three systematic reviews have evaluated the results of trials comparing restrictive versus liberal transfusion thresholds in preterm infants admitted to intensive care units. All three reviews found no significant difference in short term morbidity and mortality between neonates transfused at restrictive or liberal thresholds. However, the studies included were underpowered to investigate long term outcomes of neonates transfused at restrictive thresholds, and again, were not in actively bleeding patients (42-44).

Conflicting data from studies have resulted in uncertainty surrounding neurological outcomes in neonates transfused at more restrictive thresholds (45-47). The results of two ongoing trials, the Transfusion of Prematures (TOP) trial (48) and the Effects of Transfusion Thresholds on Neurocognitive Outcome of Extremely

Low Birth Weight Infants trial (ETTNO) trial (49) may soon add to the growing knowledge base and address this disparity.

1.6. The role of patient blood management programmes

Current international guidelines are heterogenous as they are informed by limited scientific data and are hence based more on expert opinion. Therefore paediatric transfusion practices vary widely between countries and institutions, especially in the management of neonates (50). The SANBS Clinical Guidelines for the Use of Blood Products in South Africa recommends transfusion in an acutely bleeding infant, less than four months old, when more than 10% of the blood volume is lost (29). Recommended transfusion triggers for anaemia or in infants receiving mechanical ventilation are Hb levels less than or equal to 12 g/dl (29). The transfusion trigger in infants not requiring mechanical ventilation is stated as a Hb level less than or equal to 8 - 11 g/dl (51).

An overview of other international transfusion thresholds is shown in Table 1 below. The University of Kwazulu-Natal School of Clinical Medicine has published guidelines for neonatal and paediatric transfusion that are in agreement with the SANBS guidelines (51) as shown in Table 2 below. However, the University of the Witwatersrand as well as Chris Hani Baragwanath Academic Hospital (CHBAH) currently have no institutional guidelines to inform practice in this regard. In order to optimise the care of patients requiring transfusion, a PBM programme should be developed. This will provide an opportunity to optimise care by avoiding unnecessary transfusions and limiting the potential for adverse effects (39). In order to develop a robust PBM programme, current institutional transfusion practice needs to be audited.

Table 1: Overview of international guidelines and triggers for RPC transfusion in neonates - Adapted from Updates in Red Blood Cell and Platelet Transfusions in Preterm Neonates (38).

Postnatal age	British Committee for Standards in Haematology (2016)		Australian National Blood Authority (2016)		Canadian Blood Service (2017)		Dutch Guidelines Quality Council (2019)	
	Resp support	No resp support	Resp support	No Resp support	Resp support	No Resp support	Resp support	No resp support
Week 1	10-12 g/dl	10 g/dl	11-13 g/dl	10-12 g/dl	11.5 g/dl	10 g/dl	11.5 g/dl	10 g/dl
Week 2	9.5-10 g/dl	7.5 g/dl	10-12.5 g/dl	8.5-11 g/dl	10 g/dl	8.5 g/dl	10 g/dl	8.5 g/dl
Week 3	8.5-10 g/dl	7.5 g/dl	8.5-11 g/dl	7-10 g/dl	8.5 g/dl	7.5 g/dl	8.5 g/dl	7.5 g/dl

Table 2: Overview of local guidelines and triggers for RPC transfusion in infants < 4months of age - Adapted from SANBS Clinical Guidelines for the Use of Blood Products in South Africa (29) and University of Kwazulu-Natal School of Clinical Medicine Guidelines for Neonatal & Paediatric Transfusion (51).

South African National Blood Services (2014)		University of Kwazulu-Natal School of Clinical Medicine (2016)	
Clinical condition	Trigger	Clinical condition	Trigger
Anaemia in the first 24 hours	< 12 g/dl	Preterm/term born anaemic	12 g/dl
Mechanical ventilation	< 12 g/dl	Severe pulmonary disease	12-14 g/dl
Acute blood loss	> 10% blood volume lost	Acute blood loss > 10% estimated blood volume	12 g/dl
Oxygen dependant (not ventilated)	< 8-11 g/dl	Chronic oxygen dependency	11 g/dl
Late anaemia, stable patient (off oxygen)	> 7 g/dl	Late anaemia stable patient	7 g/dl

2. Problem statement

Neonates undergoing surgery are at risk of requiring RPC transfusion owing to their relatively high metabolic needs, small circulatory volumes and inability to compensate for tissue oxygen demands in the face of anaemia (10). RPC transfusion may reduce myocardial workload (11-13), the incidence of postoperative apnoeic episodes (14) and the need for intermittent positive pressure ventilation (15). Transfusion is also associated with an increased risk of morbidity and mortality in this patient subgroup. Evidence based PBM programs aim to optimise patient care by avoiding unnecessary transfusions and limiting adverse effects (39).

Currently, there is a paucity of literature specific to PBM in children with limited evidence based guidelines (52). Various national and institutional paediatric transfusion guidelines vary in their recommendations regarding safe restrictive transfusion thresholds, particularly in the neonatal subgroup (38). While neonates undergo surgery and receive RPC transfusion at CHBAH, no departmental or institutional guidelines exist to guide intraoperative RPC transfusion practice. Intraoperative RPC transfusion practice in neonatal surgery has not been audited at CHBAH before. In order to improve patient care and avoid unnecessary transfusions, current practice needs to be audited and compared to current evidence based national and international guidelines.

3. Aim

The aim of this study is to audit the practice of intraoperative RPC transfusion in neonates presenting for surgery at CHBAH.

4. Objectives

The primary objectives of this study are to:

- describe the frequency of RPC transfusion in neonatal surgery at CHBAH
- describe the patients' Hb level before surgery
- describe the volume of RPCs transfused intraoperatively
- describe the patients' Hb level after RPC transfusion at re-admission to ICU

- describe the volume of RPCs transfused according to the patients' weight

5. Research assumptions

The following definitions will be used in this study.

Neonate: is a paediatric patient from birth until one month old.

Premature neonate: is a neonate born before 37 completed weeks of gestation.

Anaesthetist: is any qualified doctor working in the Department of Anaesthesiology including medical officers, registrars and consultants.

Patient records: will include the patient's anaesthetic chart surgical notes and ICU charts.

6. Demarcation of study field

The study will be conducted in the theatre complex of CHBAH affiliated to the Department of Anaesthesiology at the University of the Witwatersrand. CHBAH is a 2888 bed central hospital. The hospital has 25 theatres, of which one is for neonatal surgery.

7. Ethical considerations

Approval to conduct the study will be obtained from the Human Research Ethics Committee (Medical) and the Graduate Studies Committee of the University of the Witwatersrand. Permission to conduct the study will be requested from the Medical Advisory Committee of Chris Hani Baragwanath Academic Hospital (Appendix A). Permission will be requested from the Head of the Department of Anaesthesiology to access anaesthetic records (Appendix B).

The study is a retrospective review of patient records and no consent will be requested from the patients. The following steps will be taken to ensure anonymity of the data collected.

- A list of patients included in the study will be generated.
- Each patient will be allocated a study number.

- Patient's study numbers will be recorded on the data collection sheet.
- Patient names and hospital numbers will not be recorded on the data collection sheet.
- The list of patient names, hospital numbers and study numbers will be kept separately from the data collection sheet.

The following steps will be taken to ensure confidentiality of the data collected.

- Only the researcher and supervisors will have access to the raw data.
- Data will be stored securely on a password protected electronic database for six years after completion of the study.

The study will be conducted according to the principles of the Declaration of Helsinki (53) and the South African Guidelines for Good Clinical Practice (54).

8. Research methodology

8.1. Research design

A retrospective, contextual, descriptive research design will be followed in this study.

Retrospective study designs “measure variables that have occurred in the past.” (55) This is a retrospective study because historical intraoperative transfusion practices will be audited from patient records from 1 January 2015 to 31 December 2019.

This is a contextual study because it focuses on a specific group of patients within a specific location (56). The context of this study is neonates presenting for surgery at CHBAH.

A descriptive study is one in which data is gathered from a representative sample population in order to describe a phenomenon that occurs naturally in the population (55). None of the variables are manipulated by the researcher. This is a descriptive study because intraoperative RPC transfusion practice will be described by data gathered from records of neonates that presented for surgery at CHBAH.

8.2. Study population

The study population consists of all neonates who underwent surgery at CHBAH from 1 January 2015 to 31 December 2019.

8.3. Study sample

Sample method

In this study, a consecutive, convenience sampling method will be used. Endacott (57) describes convenience sampling as "The use of the most readily accessible individuals or units in a study." Consecutive sampling is a type of non-random convenience sampling which includes all available individuals or events within an accessible population (57). This study will utilise consecutive, convenience sampling because patient records for each neonate that underwent surgery at CHBAH during the period from 1 January 2015 to 31 December 2019 will be audited and included in the study. A list of available patient records will be cross checked against the neonatal theatre surgical register to ensure that all available records are included in the study sample.

Sample size

Data from patients' records in the period between 1 January 2015 to 31 December 2019 will be collected. An estimated sample size of 500 is envisaged from preliminary scoping performed where it was established that approximately 20 neonatal surgeries are performed per two-month period.

Inclusion and exclusion criteria

The inclusion criteria for this study will be:

- Records of all neonates that underwent surgery at CHBAH from 1 January 2015 until 31 December 2019.

The exclusion criteria for this study will be:

- Missing patient records
- Patient records missing important and significant data

- Illegible patient records

8.4. Collection of data

The data collection process will begin only after approval from the Ethics Committee has been granted, together with institutional and departmental permissions to access patient records. The researcher will review all records and exclude those that do not satisfy the study inclusion criteria. Study numbers will be assigned to each of the patient records to be included. Only the relevant data will be collected and entered onto a Microsoft Excel® spreadsheet (Appendix C). The following data will be collected:

- demographics (chronological age, post-conceptual age, gender, weight)
- comorbidity
- preoperative Hb
- volume of PRC transfused by the anaesthetist intraoperatively
- post-transfusion Hb

9. Data analysis

The data will be analysed with the aid of a biostatistician, using descriptive and inferential statistics. Data analysis will be performed using Stata/SE 16 statistical software (Copyright 1985 - 2019 Stata Corp LLC, Stata Corp, 4905 Lakeway Drive College Station, Texas 77845). Means and standard deviations will be used to describe the continuous variables when the data is normally distributed. Medians and interquartile ranges will be used to describe the continuous variables when the data is not normally distributed. Categorical data will be described with frequencies and percentages. Inferential statistics will be used to analyse study subsets where feasible. Student's t-test will be used to analyse parametric data while Mann-Whitney U test will be used to analyse nonparametric data. Categorical data will be analysed using the Chi-squared test. A p-value of less than 0.05 will be considered as statistically significant.

10. Significance of the study

Current intraoperative RPC transfusion practice varies. With blood being a scarce resource and the potential for causing harm from adverse outcomes related to blood transfusion, RPC should only be transfused when appropriate. PBM programmes serve to aid the clinician in appropriate transfusion and standardise transfusion practice (39). Integral to developing a PBM programme, blood utilisation needs to be reviewed and audited. Furthermore, current practice needs to be assessed to ensure adherence to recommendations (39).

This study aims to describe intraoperative utilisation of RPC in neonatal surgery at CHBAH. In so doing, it will draw attention to current transfusion practices at the institution. A comparison of the study findings to current recommendations may reveal areas for improvement in intraoperative transfusion practice in neonatal surgery with potential reduction in the number of unnecessary transfusions. Together with further study, the audit may form the basis for the future development of an institutional PBM programme.

11. Validity and reliability of the study

A valid study is one in which the measurements and conclusion are justifiable based on the study design and its interpretation (58). Furthermore, the validity of a study is indicated by whether the study measured what was intended to be measured. The lower the nonrandom or systematic errors in the study process, the greater the validity (59). Reliability refers to how consistently a measure was achieved (58). The fewer the random errors in the study process, the greater the reliability (59).

The following measures will ensure validity and reliability of the study.

- An appropriate study design will be used.
- A single researcher will collect all of the study data.
- A standardised electronic data collection sheet will be used.
- Every 10th data entry point will be checked.
- The data will be analysed in conjunction with a biostatistician.

In order to improve the validity and reliability of this study, a scoping study was performed. To assess whether the required patient data would be obtainable from patient records, the anaesthetic charts of all neonates that underwent surgery at CHBAH, over a two month period, were reviewed. A record number was assigned to each of anaesthetic charts. Data fields for patient age, weight, procedure, preoperative Hb level, estimated blood loss, volume of blood transfused, post-transfusion blood gas Hb level and post-transfusion formal Hb level were noted to be either, complete or incomplete and entered as such onto a Microsoft Excel® spreadsheet (Appendix D). No patient names, hospital numbers or data was recorded. Of the significant data needed, approximately 90% was obtained.

12. Potential limitations of the study

The study is limited by the availability of complete, legible and accurate patient records. Incomplete, illegible or missing records may result in patient exclusion from the study. Furthermore, the study will be conducted within the context of neonatal surgery at CHBAH. Hence, the study findings may not be applicable to other paediatric patients or neonates undergoing surgery at other institutions.

13. Project outline

Table 3: Overview of projected project timeline

Activity	Jan-Feb 2021	Mar 2021	Apr 2021	May 2021	Jun 2021	Jul 2021	Aug 2021	Sep 2021	Oct 2021	Nov 2021
Proposal preparation	X									
Literature review	X									
Proposal submission	X									
Ethics approval		X	X							
Postgraduate approval		X	X							
Data collection				X	X					
Data analysis						X	X			
Draft article								X	X	
Submission										X

14. Financial plan

The Department of Anaesthesiology will bear the cost of printing and paper.

Table 4: Overview of projected cost

Item	Price per page	Number of pages	Copies	Total
Proposal	R1	25	10	R250
Ethics	R1	10	25	R250
Post graduate form	R1	2	6	R12
Complete report	R1	100	4	R400
Grand total				R912

15. References

1. Mannucci PM, Levi M. Prevention and treatment of major blood loss. *N Engl J Med*. 2007;356(22):2301-11. <https://doi.org/10.1056/NEJMra067742>.
2. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. *Anesthesiology*. 2006;105(1):198-208. <https://doi.org/10.1097/00000542-200607000-00030>.
3. Bhananker SM, Ramamoorthy C, Geiduschek JM, Posner KL, Domino KB, Haberkern CM, et al. Anesthesia-related cardiac arrest in children: update from the Pediatric Perioperative Cardiac Arrest Registry. *Anesth Analg*. 2007;105(2):344-50. <https://doi.org/10.1213/01.ane.0000268712.00756.dd>.
4. Keung CY, Smith KR, Savoia HF, Davidson AJ. An audit of transfusion of red blood cell units in pediatric anesthesia. *Paediatr Anaesth*. 2009;19(4):320-8. <https://doi.org/10.1111/j.1460-9592.2009.02939.x>.
5. Venkatesh V, Khan R, Curley A, New H, Stanworth S. How we decide when a neonate needs a transfusion. *Br J Haematol*. 2013;160(4):421-33. <https://doi.org/10.1111/bjh.12095>.
6. Widness JA. Pathophysiology of anemia during the neonatal period, including anemia of prematurity. *Neoreviews*. 2008;9(11):e520-e. <https://doi.org/10.1542/neo.9-11-e520>.
7. O'Brien RT, Pearson HA. Physiologic anemia of the newborn infant. *J Pediatr*. 1971;79(1):132-8. [https://doi.org/10.1016/S0022-3476\(71\)80076-8](https://doi.org/10.1016/S0022-3476(71)80076-8).
8. Strauss RG. Anaemia of prematurity: pathophysiology and treatment. *Blood Rev*. 2010;24(6):221-5. <https://doi.org/10.1016/j.blre.2010.08.001>.

9. Whyte RK, Jefferies AL, Canadian Paediatric Society Fetus and Newborn Committee. Red blood cell transfusion in newborn infants. *Paediatr Child Health*. 2014;19(4):213-22. <https://doi.org/10.1093/pch/19.4.213>.
10. Bharadwaj A, Khandelwal M, Kumar Bhargava S. Perioperative neonatal and paediatric blood transfusion. *Indian J Anaesth*. 2014;58:652-7. <https://doi.org/10.4103/0019-5049.144679>.
11. Bard H, Fouron J-C, Chessex P, Widness JA. Myocardial, erythropoietic, and metabolic adaptations to anemia of prematurity in infants with bronchopulmonary dysplasia. *J Pediatr*. 1998;132(4):630-4. [https://doi.org/10.1016/S0022-3476\(98\)70351-8](https://doi.org/10.1016/S0022-3476(98)70351-8).
12. Lachance C, Chessex P, Fouron J-C, Widness JA, Bard H. Myocardial, erythropoietic, and metabolic adaptations to anemia of prematurity. *J Pediatr*. 1994;125(2):278-82. [https://doi.org/https://doi.org/10.1016/S0022-3476\(94\)70211-X](https://doi.org/https://doi.org/10.1016/S0022-3476(94)70211-X).
13. Fredrickson LK, Bell EF, Cress GA, Johnson KJ, Zimmerman MB, Mahoney LT, et al. Acute physiological effects of packed red blood cell transfusion in preterm infants with different degrees of anaemia. *Arch Dis Child Fetal Neonatal Ed*. 2011;96(4):F249-F53. <https://doi.org/10.1136/adc.2010.191023>.
14. Stute H, Greiner B, Linderkamp O. Effect of blood transfusion on cardiorespiratory abnormalities in preterm infants. *Arch Dis Child Fetal Neonatal Ed*. 1995;72(3):F194-6. <https://doi.org/10.1136/fn.72.3.f194>.
15. Bell EF, Strauss RG, Widness JA, Mahoney LT, Mock DM, Seward VJ, et al. Randomized Trial of Liberal Versus Restrictive Guidelines for Red Blood Cell Transfusion in Preterm Infants. *Pediatrics*. 2005;115(6):1685. <https://doi.org/10.1542/peds.2004-1884>.
16. Zagol K, Lake DE, Vergales B, Moorman ME, Paget-Brown A, Lee H, et al. Anemia, apnea of prematurity, and blood transfusions. *J Pediatr*. 2012;161(3):417-21.e1. <https://doi.org/10.1016/j.jpeds.2012.02.044>.

17. Stainsby D, Jones H, Wells AW, Gibson B, Cohen H, on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. Adverse outcomes of blood transfusion in children: analysis of UK reports to the serious hazards of transfusion scheme 1996–2005. *Br J Haematol*. 2008;141(1):73-9. <https://doi.org/10.1111/j.1365-2141.2008.07022.x>.
18. Poles D, et al, on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2019 Annual SHOT Report. 2020. Available from: <https://www.shotuk.org/wp-content/uploads/myimages/SHOT-REPORT-2019-Final-Bookmarked-v2.pdf>.
19. Poles D, et al, on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2018 Annual SHOT Report. 2019. Available from: https://www.shotuk.org/wp-content/uploads/myimages/SHOT-Report-2018_Web_Version-1.pdf.
20. Lavoie J. Blood transfusion risks and alternative strategies in pediatric patients. *Paediatr Anaesth*. 2011;21(1):14-24. <https://doi.org/10.1111/j.1460-9592.2010.03470.x>.
21. Iskander IF, Salama KM, Gamaleldin RM, Seghatchian J. Neonatal RBC transfusions: Do benefits outweigh risks? *Transfus Apher Sci*. 2018;57(3):431-6. <https://doi.org/10.1016/j.transci.2018.05.007>.
22. Mohamed A, Shah PS. Transfusion associated necrotizing enterocolitis: a meta-analysis of observational data. *Pediatrics*. 2012;129(3):529-40. <https://doi.org/10.1542/peds.2011-2872>.
23. Wallenstein MB, Arain YH, Birnie KL, Andrews J, Palma JP, Benitz WE, et al. Red blood cell transfusion is not associated with necrotizing enterocolitis: a review of consecutive transfusions in a tertiary neonatal intensive care unit. *J Pediatr*. 2014;165(4):678-82. <https://doi.org/10.1016/j.jpeds.2014.06.012>.
24. Patel RM, Knezevic A, Shenvi N, Hinkes M, Keene S, Roback JD, et al. Association of red blood cell transfusion, anemia, and necrotizing enterocolitis in very low-birth-weight infants. *Jama*. 2016;315(9):889-97. <https://doi.org/10.1001/jama.2016.1204>.

25. Christensen RD, Baer VL, Lambert DK, Ilstrup SJ, Eggert LD, Henry E. Association, among very-low-birthweight neonates, between red blood cell transfusions in the week after birth and severe intraventricular hemorrhage. *Transfusion*. 2014;54(1):104-8. <https://doi.org/10.1111/trf.12234>.
26. Baer VL, Lambert DK, Henry E, Snow GL, Butler A, Christensen RD. Among very-low-birth-weight neonates is red blood cell transfusion an independent risk factor for subsequently developing a severe intraventricular hemorrhage? *Transfusion*. 2011;51(6):1170-8. <https://doi.org/10.1111/j.1537-2995.2010.02980.x>.
27. Wang Y-C, Chan O-W, Chiang M-C, Yang P-H, Chu S-M, Hsu J-F, et al. Red blood cell transfusion and clinical outcomes in extremely low birth weight preterm infants. *Pediatr Neonatol*. 2017;58(3):216-22. <https://doi.org/10.1016/j.pedneo.2016.03.009>.
28. Dani C, Martelli E, Bertini G, Pezzati M, Rossetti M, Buonocore G, et al. Effect of blood transfusions on oxidative stress in preterm infants. *Arch Dis Child Fetal Neonatal Ed*. 2004;89(5):F408. <https://doi.org/10.1136/adc.2003.037085>.
29. South African National Blood Services. Clinical guidelines for the use of blood products in South Africa. 2014. Available from: https://sanbs.org.za/wp-content/uploads/2016/09/Clinical_Guidelines_5th-Edition_2014.pdf.
30. New HV, Berryman J, Bolton-Maggs PH, Cantwell C, Chalmers EA, Davies T, et al. Guidelines on transfusion for fetuses, neonates and older children. *Br J Haematol*. 2016;175(5):784-828. <https://doi.org/10.1111/bjh.14233>.
31. National Blood Authority (NBA). Patient Blood Management Guidelines: Module 6 - Neonatal and Paediatrics. Canberra, Australia; 2016. Available from: https://www.blood.gov.au/system/files/14523_NBA-Module-6-Neonat_Paediatrics_internals_5_updated_14_May_2020.pdf.
32. Lau W. Clinical Guide to Transfusion: Canadian Blood Services. 2017. Available from: <https://professionaleducation.blood.ca/en/transfusion/guide-clinique/neonatal-and-pediatric-transfusion>.

33. Paul DA, Leef KH, Locke RG, Stefano JL. Transfusion volume in infants with very low birth weight: a randomized trial of 10 versus 20 ml/kg. *J Pediatr Hematol Oncol.* 2002;24(1):43-6.
34. Wong H, Connelly R, Day A, Flavin MP. A comparison of high and standard blood transfusion volumes in premature infants. *Acta Paediatrica.* 2005;94(5):624-5. <https://doi.org/10.1111/j.1651-2227.2005.tb01949.x>.
35. Khodabux CM, Hack KE, von Lindern JS, Brouwers H, Walther FJ, Brand A. A comparative cohort study on transfusion practice and outcome in two Dutch tertiary neonatal centres. *Transfus Med.* 2009;19(4):195-201. <https://doi.org/10.1111/j.1365-3148.2009.00934.x>.
36. Nose Y, Tamai H, Shimada S, Funato M. Haemodynamic effects of differing blood transfusion rates in infants less than 1500 g. *J Paediatr Child Health.* 1996;32(2):177-82. <https://doi.org/10.1111/j.1440-1754.1996.tb00918.x>.
37. Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev.* 2016;10:Cd002042. <https://doi.org/10.1002/14651858.CD002042.pub4>.
38. Lopriore E. Updates in red blood cell and platelet transfusions in preterm neonates. *Am J Perinatol.* 2019;36(S 02):S37-s40. <https://doi.org/10.1055/s-0039-1691775>.
39. Goel R, Cushing MM, Tobian AA. Pediatric patient blood management programs: not just transfusing little adults. *Transfus Med Rev.* 2016;30(4):235-41. <https://doi.org/10.1016/j.tmr.2016.07.004>.
40. Goobie SM, Gallagher T, Gross I, Shander A. Society for the advancement of blood management administrative and clinical standards for patient blood management programs. 4th edition (pediatric version). *Paediatr Anaesth.* 2019;29(3):231-6. <https://doi.org/10.1111/pan.13574>.

41. Lacroix J, Hebert PC, Hutchison JS, Hume HA, Tucci M, Ducruet T, et al. Transfusion strategies for patients in pediatric intensive care units. *N Engl J Med*. 2007;356(16):1609-19. <https://doi.org/10.1056/NEJMoa066240>.
42. Venkatesh V, Khan R, Curley A, Hopewell S, Doree C, Stanworth S. The safety and efficacy of red cell transfusions in neonates: a systematic review of randomized controlled trials. *Br J Haematol*. 2012;158(3):370-85. <https://doi.org/10.1111/j.1365-2141.2012.09180.x>.
43. Whyte RK, Kirpalani H, Asztalos EV, Andersen C, Blajchman M, Heddle N, et al. Neurodevelopmental outcome of extremely low birth weight infants randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion. *Pediatrics*. 2009;123(1):207-13. <https://doi.org/10.1542/peds.2008-0338>.
44. Ibrahim M, Ho SK, Yeo CL. Restrictive versus liberal red blood cell transfusion thresholds in very low birth weight infants: a systematic review and meta-analysis. *J Paediatr Child Health*. 2014;50(2):122-30. <https://doi.org/10.1111/jpc.12409>.
45. Kirpalani H, Whyte RK, Andersen C, Asztalos EV, Heddle N, Blajchman MA, et al. The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. *J Pediatr*. 2006;149(3):301-7. <https://doi.org/10.1016/j.jpeds.2006.05.011>.
46. McCoy TE, Conrad AL, Richman LC, Lindgren SD, Nopoulos PC, Bell EF. Neurocognitive profiles of preterm infants randomly assigned to lower or higher hematocrit thresholds for transfusion. *Child Neuropsychol*. 2011;17(4):347-67. <https://doi.org/10.1080/09297049.2010.544647>.
47. Nopoulos PC, Conrad AL, Bell EF, Strauss RG, Widness JA, Magnotta VA, et al. Long-term outcome of brain structure in premature infants: effects of liberal vs restricted red blood cell transfusions. *Arch Pediatr Adolesc Med*. 2011;165(5):443-50. <https://doi.org/10.1001/archpediatrics.2010.269>.
48. Kirpalani H, Bell E, D'Angio C, Hintz S, Kennedy K, Ohls R, et al. Transfusion of Prematures (TOP) Trial: Does a liberal red blood cell transfusion

strategy improve neurologically-intact survival of extremely-low-birth-weight infants as compared to a restrictive strategy? 2012.

https://doi.org/https://www.nichd.nih.gov/sites/default/files/about/Documents/TOP_Protocol.pdf.

49. The 'Effects of Transfusion Thresholds on Neurocognitive Outcome of Extremely Low Birth-Weight Infants (ETTNO)' Study: Background, Aims, and Study Protocol. *Neonatology*. 2012;101(4):301-5.

<https://doi.org/10.1159/000335030>.

50. Bednarek FJ, Weisberger S, Richardson DK, Frantz ID, Shah B, Rubin LP. Variations in blood transfusions among newborn intensive care units. SNAP II Study Group. *J Pediatr*. 1998;133(5):601-7. [https://doi.org/10.1016/s0022-3476\(98\)70097-6](https://doi.org/10.1016/s0022-3476(98)70097-6).

51. Mpofu A. Guidelines For Neonatal & Paediatric Transfusion. University of Kwazulu-Natal; 2016. Available from:

http://anaesthetics.ukzn.ac.za/Libraries/ICU_1/FMM_4_26-02-2016_Guidelines_for_Neonatal_paediatric_transfusion_Mpofu.sflb.ashx.

52. Roseff SD, Luban NL, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. *Transfusion*. 2002;42(11):1398-413.

<https://doi.org/10.1046/j.1537-2995.2002.00208.x>.

53. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *Jama*. 2013;310(20):2191-4. <https://doi.org/10.1001/jama.2013.281053>.

54. Department of Health. Guidelines for good practice in the conduct of clinical trials with human participants in South Africa. Pretoria, South Africa: Government of South Africa; 2006. Available from: https://www.sahpra.org.za/wp-content/uploads/2020/02/1_SA-GCP-Guidelines_2nd-edition_2006-1.pdf.

55. Brink H, Van der Walt C, Van Rensburg G. Fundamentals of Research Methodology for Health Care Professionals: Juta; 2006.

56. De Vos A, Strydom H. Research at Grass Roots: A Primer for the Caring Professions: J.L. van Schaik; 1998.
57. Endacott R, Botti M. Clinical research 3: Sample selection. *Accid Emerg Nurs.* 2007;15(4):234-8. <https://doi.org/10.1016/j.aaen.2006.12.006>.
58. Botma Y, Greeff M, Mulaudzi M, Wright S. Research in Health Sciences. Cape Town: Pearson Education South Africa; 2010.
59. Nelson AA, Jr. Research design: measurement, reliability, and validity. *Am J Hosp Pharm.* 1980;37(6):851-7. <https://doi.org/10.1093/ajhp/37.6.851>.

16. Appendices

Appendix A: Letter to Medical Advisory Committee of Chris Hani Baragwanath Academic Hospital

Attention: Medical Advisory Committee

Chris Hani Baragwanath Academic Hospital

26 Chris Hani Road

Johannesburg

1864

11 March 2021


Re: Permission to conduct an audit of intraoperative red packed cell transfusion practice on neonates who underwent surgery at Chris Hani Baragwanath Academic Hospital.

Dear Sir/Madam,

My name is Kushal Govender. I am a registrar in the Department of Anaesthesiology and currently registered for a Masters in Medicine (MMed) with the University of the Witwatersrand. My research project is a retrospective audit of intraoperative red packed cell transfusion practices in neonates who underwent surgery at Chris Hani Baragwanath Academic Hospital from 1 January 2015 to 31 December 2019.

I hereby request permission to conduct my research at Chris Hani Baragwanath Hospital. There will be no additional cost to the hospital, and anonymity and confidentiality will be maintained throughout the process. The study has been approved by the Postgraduate Committee and the Human Research Ethics Committee (Medical).

Regards,



Dr Kushal Govender (Registrar)

Email: lahsuk@gmail.com

Cell: 0835425295

Appendix B: Letter to Head of Department of Anaesthesiology at Chris Hani Baragwanath Academic Hospital

Attention: Head of the Department of Anaesthesiology

Chris Hani Baragwanath Academic Hospital

26 Chris Hani Road

Johannesburg

1864

11 March 2021


Re: Permission to access anaesthetic records.

Dear Dr Palesa Mogane,

My name is Kushal Govender. I am a registrar in the Department of Anaesthesiology and currently registered for a Masters in Medicine (MMed) with the University of the Witwatersrand. My research project is a retrospective audit of intraoperative red packed cell transfusion practices in neonates who underwent surgery at Chris Hani Baragwanath Academic Hospital from 1 January 2015 to 31 December 2019. The research will only be conducted after approval by the Postgraduate Committee and the Human Research Ethics Committee (Medical).

I hereby request permission to access the anaesthetic charts of neonates who underwent surgery at Chris Hani Baragwanath Hospital from 1 January 2015 to 31 December 2019, in order to proceed with my study. Anaesthetic charts will be reviewed on the premises. Anonymity and confidentiality will be maintained as both patient and clinician identity will not be included in the study.

Regards,



Dr Kushal Govender (Registrar)

Email: lahsuk@gmail.com

Cell: 0835425295

Appendix C: Example of data collection sheet

Patient Number		
Demographics		
Gestational age at birth (weeks)		
Chronological age (days)		
Gender		
Weight (grams)		
Preoperative		
Comorbidity/ies		
Preoperative Hb (g/dl)		
Intraoperative		
Indication for surgery		
Surgical procedure		
Total anaesthesia time		
Est volume of RPC transfused (ml)		
Est volume of clear fluid (ml)		
Post-transfusion ABG Hb (g/dl)		
Post-transfusion ABG Haematocrit		
Postoperative ABG Lactate		
Postoperative ABG pH		
Postoperative ABG CO2		
Postoperative ABG O2		
Postoperative ABG Base Excess		
Postoperative Destination (ICU)	Yes	No
Intubation and ventilation	Yes	No
Inotrope/Vasopressor support	Yes	No

Appendix D: Data collection sheet for the review of patient records over a two-month period

Record number	Complete data field?						If transfused			
	Age	Weight	Procedure	Preoperative Hb	Estimated blood loss	Transfused	Volume	Post-transfusion Hb		
								Blood gas	Formal	
1	Yes	Yes	Yes	Yes	No	No				
2	Yes	Yes	Yes	Yes	No	yes	Yes	Yes	No	
3	Yes	Yes	Yes	Yes	No	No				
4	Yes	Yes	Yes	No	No	No				
5	Yes	Yes	Yes	Yes	Yes	No				
6	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	
7	Yes	Yes	Yes	Yes	No	No				
8	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	
9	Yes	Yes	Yes	No	No	Yes	No	Yes	No	
10	Yes	Yes	Yes	No	No	No				
11	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	
12	Yes	Yes	Yes	Yes	No	No				
13	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	
14	Yes	Yes	Yes	Yes	Yes	No				
15	Yes	Yes	Yes	Yes	No	No				
16	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	
17	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	
18	Yes	Yes	Yes	Yes	No	No				
19	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	
20	Yes	Yes	Yes	Yes	No	No				
21	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	
22	Yes	No	Yes	Yes	No	No				
Total	22	22	21	22	19	4	10	9	10	0

There were 22 records of neonates that underwent surgery at CHBAH during the two month period. 10 of the 22 patients (45%) were transfused RPC's during the surgery. All 22 records (100%) contained data reflecting patient's age and procedure. 21 records (95%) contained data reflecting patient's weight while 19 records (86%) contained data reflecting patient's preoperative Hb level. Only 4 records (18%), however, contained data detailing estimated blood loss. 9 of the 10 records (90%) of patients that underwent transfusion contained data reflecting the volumes of RPC transfused while all 10 of the records (100%) contained post-transfusion Hb levels from a blood gas.

Appendix 4: Clearance from Human Research Ethics Committee



R49 Dr K Govender

HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL) CLEARANCE CERTIFICATE NO. M210419

NAME: Dr K Govender
(Principal Investigator)

DEPARTMENT: School of Clinical Medicine
Department of Anaesthesia
Medical School
University


PROJECT TITLE: *An audit of the practice of red packed cell transfusion in neonatal surgery in an academic hospital*

DATE CONSIDERED: 2021/04/30

DECISION: Approved unconditionally

CONDITIONS:

SUPERVISOR: Drs P Motshabi and E Kemp

APPROVED BY: 
Dr CB Penny, Chairperson, HREC (Medical)


DATE OF APPROVAL: 2021/06/07

This Clearance Certificate is valid for 5 years from the date of approval. An extension may be applied for.

DECLARATION OF INVESTIGATORS

To be completed in duplicate and **ONE COPY** returned to the Research Office secretariat on the 3rd floor, Phillip Tobias Building, Parktown, University of the Witwatersrand, Johannesburg.

I/we fully understand the conditions under which I am/we are authorized to carry out the above-mentioned research and I/we undertake to ensure compliance with these conditions. Should any departure be contemplated from the research protocol as approved, I/we undertake to submit details to the Committee. **I agree to submit a yearly progress report.** When a funder requires annual re-certification, the application date will be one year after the date when the study was initially reviewed. In this case, the study was initially reviewed in **April** and therefore reports and re-certification will be due in the month of **April** each year. Unreported changes to the study may invalidate the clearance given by the HREC (Medical).


Signature of Principal Investigator

2021/06/08
Date

Appendix 5: Approval from Graduate Studies Committee



Private Bag 3 Wits, 2050
Fax: 027117172119
Tel: 02711 7172076

Reference: Mrs Sandra Benn
E-mail: sandra.benn@wits.ac.za

11 May 2021
Person No: 0604091X
PAG

Dr K Govender
6 Kelly Krest
13 Kelly Road
Bedfordview
2007
South Africa

Dear Dr Kushal Govender

Master of Medicine in Anaesthesia: Approval of Title

We have pleasure in advising that your proposal entitled *An Audit of the practice of red packed cell transfusion in neonatal; surgery in an academic hospital*. has been approved. Please note that any amendments to this title have to be endorsed by the Faculty's higher degrees committee and formally approved.

Yours sincerely

A handwritten signature in black ink, appearing to read 'S Benn', with a horizontal line underneath.

Mrs Sandra Benn
Faculty Registrar
Faculty of Health Sciences

Appendix 6: Permission from Medical Advisory Committee



GAUTENG PROVINCE
HEALTH
REPUBLIC OF SOUTH AFRICA

MEDICAL ADVISORY COMMITTEE

CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL

PERMISSION TO CONDUCT RESEARCH

Date: 16th March 2021

TITLE OF PROJECT:

An Audit of the practice of packed red cell transfusion in neonatal surgery in an academic hospital.

UNIVERSITY: Witswatersrand

Principal Investigator: Dr K. Govender

Department: Anaesthesia


Supervisor : Dr E Kemp


Permission Head Department (where research conducted): Yes

NHRD No.

The Medical Advisory Committee recommends that the said research be conducted at Chris Hani Baragwanath Academic Hospital. The CEO / management of Chris Hani Baragwanath Academic Hospital is accordingly informed and the study is subject to:-

- **Permission having been granted by the Committee for Research on Human Subjects of the University of the Witwatersrand.**
- The Hospital will not incur extra costs as a result of the research being conducted on its patients within the hospital
- The MAC will be informed of any serious adverse events as soon as they occur
- Permission is granted for the duration of the Ethics Committee Approval.


.....
Recommended
(On behalf of the MAC)
Date: 16/03/2021


.....
Approved/Not Approved
Hospital Management
Date: 16/03/2021

Appendix 7: Permission from Department of Anaesthesiology



GAUTENG PROVINCE

HEALTH
REPUBLIC OF SOUTH AFRICA

CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL

DIRECTORATE - ANAESTHESIA

Enquiries: Dr P. Mogane

Tel. number: (011) 933-9334

Email: Palesa.Mogane@wits.ac.za



Department of Anaesthesiology
Chris Hani Baragwanath Academic Hospital
PO Bertsham
2013
11th March 2021

To whom it may concern

RE: PERMISSION TO CONDUCT RESEARCH

This serves to confirm that I grant permission for Dr Kushal Govender i to conduct research involving the Department of Anaesthesia at the Chris Hani Baragwanath Academic Hospital. The research topic is titled: **An audit of the practice of red packed cell transfusion in neonatal surgery in an academic hospital.**

I'd like to wish him luck in this endeavor and I am happy to support him wherever possible.

Kind regards.

A handwritten signature in black ink, appearing to read 'P. Mogane'.

Dr Palesa Mogane
Chief specialist and Head of Department
Department of Anaesthesiology
Chris Hani Baragwanath Academic Hospital
University of Witwatersrand
Email: Palesa.Mogane@wits.ac.za

Appendix 8: Permission from Department of Paediatric Surgery



GAUTENG PROVINCE

HEALTH
REPUBLIC OF SOUTH AFRICA

CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL

Directorate: Paediatric Surgery

Enquiries: Prof. J.A. Loveland

Tel. number: (011)933 8138; Email: Loveland@wol.co.za

17 May 2021

Dear Dr Kushal Govender,

RE: PROVISIONAL PERMISSION TO CONDUCT A STUDY

Your request to conduct a case report titled "**An audit of the practice of red packed cell transfusion in neonatal surgery in an academic hospital**", intended for your Ethics application, on a Paediatric Surgery Patient at Chris Hani Baragwanath Academic Hospital is provisionally granted pending full ethics clearance from Wits HREC and CHBAH CEO. You therefore can obtain relevant information from patient's files once full Ethics clearance is obtained. Please be advised that you are to submit a full copy of your final protocol and final Ethics Clearance Certificate from Wits HREC before you are to commence data collection.

While it is recognised that research projects should comprise the researcher's work only and that publication of such work is encouraged, in the event that the information used comprises the diagnosis and management from anaesthetics, then joint authorship from a member of staff from the Department of Paediatric Surgery would not be required. However, should additional information such as management by Paediatric surgery (such as operative intervention, management and follow-up as conducted by the Department of Paediatric Surgery) be extracted from the report, it would be expected that this would be done in conjunction with a member of staff in the Department of Paediatric surgery and that joint authorship would follow in resulting publications. It is requested that you communicate your requirements with the Department of Paediatric Surgery in this regard.

Wishing you the best in your research endeavour and assuring you our assistance in this research project.

Kind regards,

Dr A. Withers

Operational Head of Research
Department of Paediatric Surgery,
Chris Hani Baragwanath Academic Hospital
University of the Witwatersrand

Professor JA Loveland

Academic Head
Department of Paediatric Surgery
School of Clinical Medicine
University of the Witwatersrand

Appendix 9: Turnitin report

K Govender - An audit of the practice of red packed cell transfusion in neonatal surgery in an academic hospital-3.pdf

ORIGINALITY REPORT

13%

SIMILARITY INDEX

11%

INTERNET SOURCES

9%

PUBLICATIONS

2%

STUDENT PAPERS

PRIMARY SOURCES

1	hdl.handle.net Internet Source	1%
2	www.ncbi.nlm.nih.gov Internet Source	1%
3	"SCIENTIFIC ABSTRACTS", Journal of General Internal Medicine, 2010 Publication	1%
4	etpha.org Internet Source	1%
5	Submitted to Adtalem Global Education Student Paper	1%
6	Goel, Ruchika, Melissa Cushing, and Aaron A.R. Tobian. "Pediatric Patient Blood Management Programs: Not Just Transfusing Little Adults", Transfusion Medicine Reviews, 2016. Publication	1%
7	www.oncotarget.com Internet Source	1%